Sibylle Loibl*
#118,534
Most Influential Person Now
Sibylle Loibl*'s AcademicInfluence.com Rankings
Sibylle Loibl*philosophy Degrees
Philosophy
#5274
World Rank
#8032
Historical Rank
Logic
#2580
World Rank
#3592
Historical Rank

Download Badge
Philosophy
Sibylle Loibl*'s Degrees
- Doctorate Medicine University of Vienna
Why Is Sibylle Loibl* Influential?
(Suggest an Edit or Addition)Sibylle Loibl*'s Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis (2014) (2895)
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 (2013) (2859)
- Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. (2012) (1966)
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. (2015) (1875)
- Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. (2010) (1377)
- Trastuzumab Emtansine for Residual Invasive HER2‐Positive Breast Cancer (2019) (1209)
- Alpelisib for PIK3CA‐Mutated, Hormone Receptor–Positive Advanced Breast Cancer (2019) (1081)
- Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. (2014) (1032)
- Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. (2018) (1030)
- Association analysis identifies 65 new breast cancer risk loci (2017) (922)
- Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. (2015) (800)
- Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. (2014) (751)
- Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer (2018) (674)
- Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. (2006) (671)
- De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 (2018) (639)
- Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. (2015) (634)
- Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials (2018) (614)
- Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. (2019) (584)
- Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes (2018) (559)
- Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. (2009) (532)
- Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. (2010) (513)
- Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. (2016) (503)
- Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer (2009) (499)
- Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). (2012) (497)
- Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. (2011) (472)
- Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial (2010) (468)
- Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. (2012) (457)
- Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. (2018) (443)
- Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression. (2011) (441)
- Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. (2012) (422)
- Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothe (2017) (408)
- Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. (2021) (398)
- Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. (2007) (380)
- A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer - clinical results and biomarker analysis of GeparNuevo study. (2019) (360)
- De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. (2018) (353)
- HER2-positive breast cancer (2017) (306)
- The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial. (2018) (305)
- Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. (2021) (297)
- Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. (2016) (284)
- Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. (2011) (283)
- Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial (2017) (281)
- Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. (2008) (279)
- Estimating the Benefits of Therapy for Early Stage Breast Cancer The St Gallen International Consensus Guidelines for the Primary Therapy of Early Breast Cancer 2019. (2019) (271)
- Effect of neoadjuvant anthracycline–taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study (2010) (267)
- The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer. (2012) (265)
- Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study. (2013) (248)
- Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. (2008) (247)
- Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials (2010) (247)
- Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer (2017) (244)
- The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. (2012) (242)
- Management of venous port systems in oncology: a review of current evidence. (2008) (237)
- Breast cancer in pregnancy: recommendations of an international consensus meeting. (2010) (236)
- Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial (2020) (233)
- Response-guided neoadjuvant chemotherapy for breast cancer. (2013) (232)
- Treatment of breast cancer during pregnancy: an observational study. (2012) (226)
- PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. (2014) (222)
- ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. (2021) (215)
- Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data. (2018) (213)
- Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline (2021) (210)
- Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. (2015) (204)
- Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials (2019) (197)
- Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. (2013) (193)
- Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group (2016) (189)
- Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. (2010) (189)
- Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer (2019) (188)
- Prospective Validation of Immunological Infiltrate for Prediction of Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer – A Substudy of the Neoadjuvant GeparQuinto Trial (2013) (187)
- Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. (2011) (183)
- Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. (2019) (183)
- Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto (2018) (182)
- Second international consensus guidelines for breast cancer in young women (BCY2). (2014) (179)
- Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021 (2021) (175)
- Alpelisib Plus Fulvestrant for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: Final Overall Survival Results From SOLAR-1. (2020) (175)
- Breast cancer (2021) (174)
- Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis (2018) (173)
- Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells (2002) (172)
- Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy (2011) (170)
- Breast carcinoma during pregnancy (2006) (159)
- Breast Cancer Diagnosed During Pregnancy: Adapting Recent Advances in Breast Cancer Care for Pregnant Patients. (2015) (157)
- A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer (2018) (149)
- Advances in the treatment of advanced oestrogen-receptor-positive breast cancer (2017) (148)
- Strategies for developing Ki67 as a useful biomarker in breast cancer. (2015) (145)
- Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. (2008) (144)
- Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells. (2004) (136)
- ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer (2020) (134)
- Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer (2016) (133)
- Surgery for Recurrent Ovarian Cancer: Role of Peritoneal Carcinomatosis: Exploratory Analysis of the DESKTOP I Trial About Risk Factors, Surgical Implications, and Prognostic Value of Peritoneal Carcinomatosis (2009) (130)
- Breast cancer in pregnancy (2012) (129)
- Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial (2016) (128)
- PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer--results at the time of surgery. (2011) (127)
- Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast (2008) (124)
- First international consensus guidelines for breast cancer in young women (BCY1). (2014) (124)
- Ki67 Measured after Neoadjuvant Chemotherapy for Primary Breast Cancer (2013) (123)
- Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44). (2013) (120)
- Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†. (2014) (118)
- PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer--outcome on prognosi (2011) (116)
- Treatment of Pregnant Breast Cancer Patients and Outcomes of Children Exposed to Chemotherapy In Utero (2007) (113)
- Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy. (2019) (111)
- Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy (2009) (111)
- Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer (2009) (111)
- Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial (2014) (110)
- Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. (2021) (108)
- The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practice (2020) (108)
- Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study. (2015) (107)
- Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo. (2020) (106)
- Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial (2018) (104)
- Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. (2021) (104)
- PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. (2016) (100)
- Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC) (2012) (99)
- 13th St. Gallen International Breast Cancer Conference 2013: Primary Therapy of Early Breast Cancer Evidence, Controversies, Consensus - Opinion of a German Team of Experts (Zurich 2013) (2013) (97)
- Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results. (2017) (97)
- Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients--a double-blind, randomized study. (2006) (97)
- Metabolomics of human breast cancer: new approaches for tumor typing and biomarker discovery (2012) (95)
- Classical pathology and mutational load of breast cancer – integration of two worlds (2015) (93)
- Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas (2005) (93)
- Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. (2020) (93)
- Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma (2014) (90)
- Feasibility, toxicity and quality of life of first-line chemotherapy with platinum/paclitaxel in elderly patients aged >or=70 years with advanced ovarian cancer--a study by the AGO OVAR Germany. (2006) (86)
- Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis (2011) (85)
- Surgical Procedures After Neoadjuvant Chemotherapy in Operable Breast Cancer: Results of the GEPARDUO Trial (2006) (85)
- Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials (2015) (85)
- Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial (2019) (83)
- The role of early expression of inducible nitric oxide synthase in human breast cancer. (2005) (83)
- Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy. (2011) (83)
- Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) (2019) (83)
- Standardized Ki67 Diagnostics Using Automated Scoring—Clinical Validation in the GeparTrio Breast Cancer Study (2014) (83)
- German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer. (2013) (83)
- Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials (2021) (81)
- Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) – Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer (2018) (80)
- Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis. (2018) (80)
- Predictive value of serum interleukin‐6 and ‐8 levels in preterm labor or rupture of the membranes (2000) (80)
- Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. (2018) (79)
- NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto. (2019) (79)
- Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE). (2017) (78)
- Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): Results of the phase III SOLAR-1 trial. (2018) (77)
- Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial (2021) (76)
- Abstract S2-04: Early survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto) (2016) (76)
- BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study. (2018) (75)
- Impact of Multifocal or Multicentric Disease on Surgery and Locoregional, Distant and Overall Survival of 6,134 Breast Cancer Patients Treated With Neoadjuvant Chemotherapy (2015) (75)
- Integration of metabolomics and expression of glycerol-3-phosphate acyltransferase (GPAM) in breast cancer-link to patient survival, hormone receptor status, and metabolic profiling. (2012) (75)
- Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques (2015) (74)
- Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44). (2013) (74)
- Capecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26/BIG 3–05) (2008) (74)
- Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial (2017) (73)
- Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial. (2016) (72)
- Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial. (2019) (71)
- Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): Results from GeparSixto. (2014) (70)
- Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials (2015) (70)
- Poor Outcome in Estrogen Receptor–Positive Breast Cancers Predicted by Loss of Plexin B1 (2007) (70)
- Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer. (2005) (69)
- NO signaling confers cytoprotectivity through the survivin network in ovarian carcinomas. (2008) (69)
- Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study). (2020) (68)
- Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data. (2010) (67)
- Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history (2018) (67)
- Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01) (2012) (67)
- AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019 (2019) (67)
- Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC). (2021) (67)
- HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer (2013) (67)
- The BCY3/BCC 2017 survey on physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients. (2018) (66)
- The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR. (2006) (66)
- Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial (2016) (64)
- RANK expression as a prognostic and predictive marker in breast cancer (2014) (64)
- Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC (2005) (63)
- Surgical treatment of primary breast cancer in the neoadjuvant setting (2014) (63)
- Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial. (2011) (63)
- Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes (2014) (62)
- Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry. (2018) (62)
- Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) – Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer (2018) (61)
- Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer (2020) (60)
- De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. (2019) (60)
- Management of menopausal symptoms in breast cancer patients. (2011) (59)
- Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro). (2014) (59)
- Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences (2014) (58)
- A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies. (2010) (58)
- Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut). (2007) (57)
- Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results From the BrighTNess Randomized Clinical Trial. (2020) (56)
- Randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC). (2017) (56)
- Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group (2020) (54)
- The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group (2021) (54)
- Analysis of PIK3CA Mutations in Breast Cancer Subtypes (2014) (54)
- Correlation of various pathologic complete response (pCR) definitions with long-term outcome and the prognostic value of pCR in various breast cancer subtypes: Results from the German neoadjuvant meta-analysis. (2011) (53)
- LBA17 ASCENT: A randomized phase III study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC) (2020) (53)
- Neutrophil Gelatinase-Associated Lipocalin (NGAL) Predicts Response to Neoadjuvant Chemotherapy and Clinical Outcome in Primary Human Breast Cancer (2012) (53)
- Using ultrasound and palpation for predicting axillary lymph node status following neoadjuvant chemotherapy - Results from the multi-center SENTINA trial. (2017) (51)
- Time Course and Management of Key Adverse Events During the Randomized Phase 3 SOLAR-1 Study of PI3K Inhibitor Alpelisib Plus Fulvestrant in Patients With HR-Positive Advanced Breast Cancer. (2020) (51)
- A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). (2013) (51)
- Abstract GS3-08: Alpelisib + fulvestrant for advanced breast cancer: Subgroup analyses from the phase III SOLAR-1 trial (2019) (51)
- Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy (2016) (50)
- Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER 2-Positive Breast Cancer (2009) (50)
- S3-2: Neoadjuvant Chemotherapy Adapted by Interim Response Improves Overall Survival of Primary Breast Cancer Patients - Results of the GeparTrio Trial. (2011) (49)
- Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer (2015) (49)
- Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer. (2018) (49)
- Validation of p95 as a predictive marker for trastuzumab-based therapy in primary HER2-positive breast cancer: A translational investigation from the neoadjuvant GeparQuattro study. (2011) (48)
- Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy. (2015) (48)
- Prediction of pathological complete response (pCR) by Homologous Recombination Deficiency (HRD) after carboplatin-containing neoadjuvant chemotherapy in patients with TNBC: Results from GeparSixto. (2015) (47)
- Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials (2008) (47)
- Comparison of BEAMing and Droplet Digital PCR for Circulating Tumor DNA Analysis. (2019) (46)
- Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy. (2016) (45)
- Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial (2010) (45)
- 14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts (2015) (44)
- AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022 (2020) (44)
- A randomized phase 2 study comparing EC or CMF versus nab‐paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high‐risk early breast cancer (ICE II‐GBG 52) (2015) (44)
- Genome-wide association study of germline variants and breast cancer-specific mortality (2019) (44)
- PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. (2018) (44)
- Plasma ESR 1 Mutations and the Treatment of Estrogen Receptor – Positive Advanced Breast Cancer (2016) (43)
- Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group. (2011) (43)
- Abstract S1-05: Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC) (2013) (43)
- Neoadjuvant treatment of breast cancer--Clinical and research perspective. (2015) (42)
- The role of surgery in recurrent ovarian cancer (2005) (42)
- PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. (2019) (42)
- Abstract S1-11: Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC) (2012) (42)
- AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021 (2021) (41)
- AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021 (2021) (41)
- Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study. (2016) (41)
- Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44). (2018) (41)
- Abstract S3-1: Lapatinib vs Trastuzumab in Combination with Neoadjuvant Anthracycline-Taxane-Based Chemotherapy: Primary Efficacy Endpoint Analysis of the GEPARQUINTO STUDY (GBG 44) (2010) (40)
- Monounsaturated fatty acids in serum triacylglycerols are associated with response to neoadjuvant chemotherapy in breast cancer patients (2014) (40)
- Expression of endothelial and inducible nitric oxide synthase in benign and malignant lesions of the breast and measurement of nitric oxide using electron paramagnetic resonance spectroscopy (2002) (40)
- A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer (2018) (40)
- Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer—results from the GeparQuattro study (GBG 40) (2012) (39)
- Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance (2016) (39)
- Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials (2022) (39)
- Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane–Anthracycline Containing Chemotherapy—DAFNE (GBG-70) (2015) (39)
- Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase 3 trial. (2022) (38)
- Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer (2016) (38)
- Corrections to "De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017". (2019) (38)
- Adjuvant endocrine treatment with medroxyprogesterone acetate or tamoxifen in stage I and II endometrial cancer--a multicentre, open, controlled, prospectively randomised trial. (2002) (38)
- Taxanes in the treatment of breast cancer: Have we better defined their role in older patients? A position paper from a SIOG Task Force. (2016) (38)
- Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment (2021) (38)
- Expression of endothelial and inducible nitric oxide synthase in benign and malignant lesions of the breast and measurement of nitric oxide using electron paramagnetic resonance spectroscopy. (1999) (38)
- Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer (2020) (36)
- First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: results of the MONICA trial. (2010) (35)
- GeparOLA: A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients (pts) with HER2-negative early breast cancer (BC) and homologous recombination deficiency (H (2019) (34)
- Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab – a translational project in the neoadjuvant GeparQuinto trial (2011) (33)
- Tumor-Infiltrating Lymphocytes: A Promising Biomarker in Breast Cancer (2016) (33)
- Adjuvant T-DM1 versus Trastuzumab in Patients with Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer: Subgroup Analyses from KATHERINE. (2021) (33)
- Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials (2017) (32)
- VEGF-A and i-NOS expression are prognostic factors in serous epithelial ovarian carcinomas after complete surgical resection (2009) (32)
- Breast carcinoma during pregnancy. International recommendations from an expert meeting. (2006) (31)
- Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy (2020) (31)
- Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study (2015) (31)
- Everolimus as treatment for breast cancer patients with bone metastases only: results of the phase II RADAR study (2013) (31)
- AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019 (2019) (31)
- PALOMA3: A double-blind, phase III trial of fulvestrant with or without palbociclib in pre- and post-menopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy. (2015) (31)
- Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer: A Secondary Analysis of the GeparOcto Randomized Clinical Trial. (2020) (30)
- Phase 3 study evaluating efficacy and safety of veliparib (V) plus carboplatin (Cb) or Cb in combination with standard neoadjuvant chemotherapy (NAC) in patients (pts) with early stage triple-negative breast cancer (TNBC). (2017) (30)
- Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer. (2013) (30)
- Lucitanib for the Treatment of HR+/HER2− Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study (2019) (29)
- Side Effects of Standard Adjuvant and Neoadjuvant Chemotherapy Regimens According to Age Groups in Primary Breast Cancer (2013) (29)
- Abstract S1-06: Increased tumor-associated lymphocytes predict benefit from addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer in the GeparSixto trial (GBG 66) (2013) (29)
- Correction to: De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 (Annals of Oncology (2017) 28(8) (1700–1712), (S0923753419321817), (10.1093/annonc/mdx308)) (2017) (29)
- Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial (2018) (28)
- PREPARE trial. A randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF with a standard dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer: A preplanned interim analysis of eff (2008) (28)
- ZORO: A prospective randomized multicenter study to prevent chemotherapy-induced ovarian failure with the GnRH-agonist goserelin in young hormone-insensitive breast cancer patients receiving anthracycline containing (neo-) adjuvant chemotherapy (GBG 37). (2009) (28)
- Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox. (2021) (28)
- Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer (2020) (27)
- Outcome after neoadjuvant chemotherapy in elderly breast cancer patients – a pooled analysis of individual patient data from eight prospectively randomized controlled trials (2018) (27)
- Axillary staging for breast cancer during pregnancy: feasibility and safety of sentinel lymph node biopsy (2018) (27)
- Predictive Factors for Response to Neoadjuvant Therapy in Breast Cancer (2014) (27)
- Neoadjuvant treatment of HER2 overexpressing primary breast cancer with trastuzumab given concomitantly to epirubicin/ cyclophosphamide followed by docetaxel ± capecitabine. First analysis of efficacy and safety of the GBG/AGO multicenter intergroup-study “GeparQuattro” (2008) (27)
- Genomic correlates of response to adjuvant trastuzumab (H) and pertuzumab (P) in HER2+ breast cancer (BC): Biomarker analysis of the APHINITY trial. (2019) (27)
- Abstract P1-11-03: Pathological Complete Response after Neoadjuvant Chemotherapy + Trastuzumab Treatment Predicts Survival and Detects a Patient Subgroup at High Need for Improvement of Anti-HER2 Therapy. Three Year Median Follow-Up Data of the TECHNO Trial (2010) (26)
- Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) – Recommendations for Daily Routine Practice (2019) (26)
- Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapry in 686 triple-negative primary breast cancers: Seconday endpoint analysis of the GeparQuinto study (GBG 44). (2011) (26)
- Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials. (2021) (26)
- Locoregional recurrence (LRR) after neoadjuvant chemotherapy (NAC): Pooled-analysis results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC). (2014) (26)
- What is the current standard of care for anti-HER2 neoadjuvant therapy in breast cancer? (2012) (26)
- Abstract S3-1: Neoadjuvant Chemotherapy in the very young 35 years of age or younger (2012) (26)
- Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group (2020) (26)
- Evaluation of homologous recombination deficiency (HRD) status with pathological response to carboplatin +/- veliparib in BrighTNess, a randomized phase 3 study in early stage TNBC. (2018) (26)
- Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33) (2011) (26)
- Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29). (2016) (25)
- Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy. (2015) (24)
- Lessons from the neoadjuvant setting on how best to choose adjuvant therapies. (2011) (24)
- The definition of pregnancy-associated breast cancer is outdated and should no longer be used. (2021) (24)
- Comparison of docetaxel/doxorubicin/cyclophosphamide (tac) versus vinorelbine/capecitabine (nx) in patients non-responding to 2 cycles of neoadjuvant Tac chemotherapy - first results of the phase Iii Gepartrio-study by the German Breast Group (2005) (24)
- Efficacy of palbociclib plus fulvestrant (P+F) in patients (pts) with metastatic breast cancer (MBC) and ESR1 mutations (mus) in circulating tumor DNA (ctDNA). (2016) (24)
- Anti-cancer immune response mechanisms in neoadjuvant and targeted therapy (2011) (24)
- Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized Trials (2019) (24)
- Abstract S4-6: Neoadjuvant Chemotherapy with or without Bevacizumab: Primary Efficacy Endpoint Analysis of the GEPARQUINTO Study (GBG 44) (2010) (23)
- Abstract S2-07: A randomized phase III trial comparing neoadjuvant chemotherapy with weekly nanoparticle-based paclitaxel with solvent-based paclitaxel followed by anthracyline/cyclophosphamide for patients with early breast cancer (GeparSepto); GBG 69 (2015) (23)
- Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial. (2021) (23)
- Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus (2015) (23)
- Breast cancer during pregnancy: medical therapy and prognosis. (2008) (23)
- Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials. (2020) (23)
- Abstract S3-04: The phase III ICE study: Adjuvant Ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancer (2015) (22)
- Clinical relevance and concordance of HER2 status in local and central testing—an analysis of 1581 HER2-positive breast carcinomas over 12 years (2017) (22)
- Cost-Effectiveness Analysis of Prognostic Gene Expression Signature-Based Stratification of Early Breast Cancer Patients (2014) (22)
- S2-4: GAIN Study: A Phase III Trial To Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients with Node-Positive Primary Breast Cancer – 1st Interim Efficacy Analysis. (2011) (22)
- Update on neoadjuvant/preoperative therapy of breast cancer: experiences from the German Breast Group (2013) (22)
- German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients (2017) (22)
- Knowledge, attitudes and practice of physicians towards fertility and pregnancy-related issues in youngBRCA-mutated breast cancer patients. (2019) (22)
- Biomarker data from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer. (2020) (22)
- New Therapeutic Options for Breast Cancer during Pregnancy (2008) (22)
- Ioncopy: a novel method for calling copy number alterations in amplicon sequencing data including significance assessment (2016) (21)
- Radiological Patterns of Brain Metastases in Breast Cancer Patients: A Subproject of the German Brain Metastases in Breast Cancer (BMBC) Registry (2016) (21)
- Outcome of breast cancer patients with low hormone receptor positivity: Analysis of a 15-year population-based cohort. (2021) (21)
- Abstract GS3-05: Survival analysis of the prospectively randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy with weekly nab-paclitaxel with solvent-based paclitaxel followed by anthracycline/cyclophosphamide for patients with early breast cancer – GBG69 (2018) (21)
- LBA12 PALLAS: A randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer (2020) (21)
- Tamoxifen treatment for male breast cancer and risk of thromboembolism: prospective cohort analysis (2019) (21)
- A randomised trial of goserelin versus control after adjuvant, risk-adapted chemotherapy in premenopausal patients with primary breast cancer - GABG-IV B-93. (2007) (21)
- S5-4: pCR as a Surrogate in HER2−Positive Patients Treated with Trastuzumab. (2011) (21)
- Abstract S1-7: Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer – First efficacy results from the LEA study. (2012) (21)
- PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane–Based Neoadjuvant Chemotherapy (2020) (20)
- Abstract GS1-07: Effects of capecitabine as part of neo-/adjuvant chemotherapy. A meta-analysis of individual patient data from 12 randomized trials including 15,457 patients (2020) (20)
- Avoiding Axillary Sentinel Lymph Node Biopsy after Neoadjuvant Systemic Therapy in Breast Cancer: Rationale for the Prospective, Multicentric EUBREAST-01 Trial (2020) (20)
- Surgical Outcome after Neoadjuvant Chemotherapy and Bevacizumab: Results from the GeparQuinto Study (GBG 44) (2014) (20)
- Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group (2013) (20)
- 96O Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (T) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2+ breast cancer: Subgroup analysis from KATHERINE (2020) (20)
- Breast cancer, placenta and pregnancy. (2019) (20)
- Abstract CT039: Cyclin E1 (CCNE1)expression associates with benefit from palbociclib in metastatic breast cancer (MBC) in the PALOMA3 trial (2018) (20)
- Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer (2014) (19)
- Prospective monitoring of circulating tumor cells in breast cancer patients treated with primary systemic therapy—A translational project of the German Breast Group study GeparQuattro (2007) (19)
- The Importance of Supportive Care in Breast Cancer Patients (2014) (19)
- Anti‐epidermal growth factor receptor‐antibody therapy for treatment of breast cancer (2002) (19)
- Bevacizumab treatment for advanced breast cancer. (2011) (19)
- A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel / carboplatin followed by epirubicin / cyclophosphamide as neoadjuvant chemotherapy in patients with HER2-negative early breast cancer and homologous recombination deficiency (HRD): GeparOLA. (2016) (19)
- Abstract OT2-6-08: Phase II, randomized, parallel-cohort study of neoadjuvant buparlisib (BKM120) in combination with trastuzumab and paclitaxel in women with HER2-positive, PIK3CA mutant and PIK3CA wild-type primary breast cancer – NeoPHOEBE (2013) (18)
- AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022 (2022) (18)
- Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer (2021) (18)
- Investigations on the inducible and endothelial nitric oxide synthases in human breast cancer cell line MCF-7 - estrogen has an influence on e-NOS, but not on i-NOS. (2006) (18)
- Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy (2019) (18)
- 163PDLong-term survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative (TNBC) and HER2-positive early breast cancer (GeparSixto) (2017) (17)
- nab-Paclitaxel in patients with advanced solid tumors and hepatic dysfunction: a pilot study (2010) (17)
- Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer From SOLAR-1 (2021) (17)
- SOLAR-1: A phase III study of alpelisib + fulvestrant in men and postmenopausal women with HR+/HER2– advanced breast cancer (BC) progressing on or after prior aromatase inhibitor therapy. (2016) (17)
- Re-Challenging Taxanes in Recurrent Breast Cancer in Patients Treated with (Neo-)Adjuvant Taxane-Based Therapy (2011) (17)
- Thymosin beta 15A (TMSB15A) is a predictor of chemotherapy response in triple-negative breast cancer (2012) (17)
- Randomized, multicenter, two-dose level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody catumaxomab (anti-EpCAM x anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients (2007) (17)
- Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials. (2019) (17)
- Epirubicin/paclitaxel/carboplatin (TEC) vs paclitaxel/carboplatin (TC) in first-line treatment of ovarian cancer (OC) FIGO stages IIB-IV. An AGO-GINECO Intergroup phase III trial (2004) (16)
- Prediction of Response to Neoadjuvant Chemotherapy: New Biomarker Approaches and Concepts (2011) (16)
- Endocrine Therapy in Premenopausal Hormone Receptor Positive/Human Epidermal Growth Receptor 2 Negative Metastatic Breast Cancer: Between Guidelines and Literature. (2018) (16)
- Silencing of the HER 2 / neu Gene by siRNA Inhibits Proliferation and Induces Apoptosis in HER 2 / neu – Overexpressing Breast Cancer Cells 1 (2014) (16)
- Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer: The REACT Randomized Clinical Trial. (2021) (16)
- Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto (2019) (16)
- Efficacy and safety of nab-paclitaxel 125 mg/m2 and nab-paclitaxel 150 mg/m2 compared to paclitaxel in early high-risk breast cancer. Results from the neoadjuvant randomized GeparSepto study (GBG 69) (2017) (16)
- Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study (2022) (16)
- Abstract GS1-02: Phase III study of palbociclib combined with endocrine therapy (ET) in patients with hormone-receptor-positive (HR+), HER2-negative primary breast cancerand with high relapse risk after neoadjuvant chemotherapy (NACT): First results from PENELOPE-B (2021) (16)
- Being Pregnant and Diagnosed with Breast Cancer (2012) (16)
- Mitomycin C, 5-fluorouracil and folinic acid (Mi-Fu-Fo) as salvage chemotherapy in breast cancer patients with liver metastases and impaired hepatic function: a phase II study (2004) (15)
- Oxaliplatin and 5-fluorouracil for heavily pretreated metastatic breast cancer: a preliminary phase II study (2003) (15)
- Relationship of omission of adjuvant radiotherapy to outcomes of locoregional control and disease-free survival in patients with or without pCR after neoadjuvant chemotherapy for breast cancer: A meta-analysis on 3481 patients from the Gepar-trials. (2015) (15)
- Abstract S5-05: Postneoadjuvant treatment with zoledronate in patients with tumor residuals after anthracyclines-taxane-based chemotherapy for primary breast cancer – The phase III NATAN study (GBG 36/ABCSG XX) (2013) (15)
- Deciphering clonality in aneuploid breast tumors using SNP array and sequencing data (2014) (15)
- Abstract GS1-10: Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: Primary results from KATHERINE (2019) (15)
- Abstract PD02-06: New Molecular Biomarkers for Resistance to Trastuzumab in Primary HER2 Positive Breast Cancer — A Translational Investigation from the Neoadjuvant GeparQuattro Study (2010) (15)
- Neoadjuvant treatment of breast cancer: maximizing pathologic complete response rates to improve prognosis (2015) (14)
- Abstract S6-2: 313 Patients with Breast Cancer during Pregnancy — Results from a Prospective and Retrospective Registry (GBG-20/BIG02-03) (2010) (14)
- Tumor-infiltrating lymphocytes in breast cancer (2014) (14)
- Efficacy and safety of tailored and dose‐dense adjuvant chemotherapy and trastuzumab for resected HER2‐positive breast cancer: Results from the phase 3 PANTHER trial (2019) (14)
- PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + Anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC). (2017) (14)
- Neoadjuvant chemotherapy for early breast cancer. (2018) (14)
- A randomised phase III trial comparing two dose-dense, dose-intensified approaches (EPC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto). (2015) (14)
- Dose-dense intensified sequential versus conventionally-dosed anthracycline and taxane-containing neoadjuvant therapy in patients with inflammatory breast cancer. (2012) (14)
- Genetic landscape of resistance to CDK4/6 inhibition in circulating tumor DNA (ctDNA) analysis of the PALOMA3 trial of palbociclib and fulvestrant versus placebo and fulvestrant. (2018) (14)
- Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40). (2012) (13)
- Use of goserelin in the treatment of breast cancer (2005) (13)
- Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE). (2017) (13)
- Reactive stroma and trastuzumab resistance in HER2‐positive early breast cancer (2020) (13)
- Abstract P3-07-12: Homologous recombination deficiency (HRD) as a predictive biomarker of response to neoadjuvant platinum-based therapy in patients with triple negative breast cancer (TNBC): A pooled analysis (2016) (13)
- NSABP B-59/GBG 96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in Patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo. (2018) (13)
- Efficacy of Endocrine Therapy for the Treatment of Breast Cancer in Men: Results from the MALE Phase 2 Randomized Clinical Trial. (2021) (13)
- Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective PANTHER study with focus on obese patients (2019) (13)
- Reporting of myelotoxicity associated with emerging regimens for the treatment of selected solid tumors. (2012) (13)
- Breakthroughs in research and treatment of early breast cancer: an overview of the last three decades (2013) (13)
- Predictive value of sphingosine kinase 1 expression in neoadjuvant treatment of breast cancer (2013) (13)
- Adverse Event Management of Oral Mucositis in Patients with Breast Cancer (2014) (12)
- Abstract S5-06: BRCA mutations, therapy response and prognosis in the neoadjuvant GeparQuinto study (2016) (12)
- Cardiotoxicity and Cardiovascular Biomarkers in Patients With Breast Cancer: Data From the GeparOcto‐GBG 84 Trial (2020) (12)
- Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer (2018) (12)
- Abstract PD04-06: Changes in Circulating Tumor and Endothelial Cells in Peripheral Blood of Patients Treated in the Neoadjuvant Chemotherapy Plus Targeted Treatment Breast Cancer Study “GeparQuinto” (2010) (12)
- Breast cancer during pregnancy--A prospective and retrospective European registry (GBG-20/BIG02-03) (2008) (12)
- Gain study: A phase III trial to compare ETC versus EC-TX and ibandronate versus observation in patients with node-positive primary breast cancer. (2016) (12)
- 443 PARP is expressed in all subtypes of early breast cancer and is a predictive factor for response to neoadjuvant chemotherapy (2010) (12)
- Abstract S4-06: PIK3CA mutation predicts resistance to anti-HER2/chemotherapy in primary HER2-positive/hormone-receptor-positive breast cancer – Prospective analysis of 737 participants of the GeparSixto and GeparQuinto studies (2013) (12)
- Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial (2019) (12)
- Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC (2020) (12)
- Abstract OT2-6-11: PENELOPE: Phase III study evaluating palbociclib (PD-0332991), a cyclin-dependent kinase (CDK) 4/6 inhibitor in patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy (GBG-78/BIG1-13) (2013) (12)
- Immunohistochemical evaluation of endothelial nitric oxide synthase expression in primary breast cancer. (2005) (11)
- Systematic analysis of parameters predicting pathological axillary status (ypN0 vs. ypN+) in patients with breast cancer converting from cN+ to ycN0 through primary systemic therapy (PST) (2018) (11)
- Abstract GS3-03: A phase III multicentre double blind randomised trial of celecoxib versus placebo in primary breast cancer patients (REACT – Randomised EuropeAn celecoxib trial) (2018) (11)
- Patient‐reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2–positive breast cancer (2020) (11)
- Peripheral neuropathy (PN), thrombocytopenia (TCP) and central nervous system (CNS) recurrence: An update of the phase III KATHERINE trial of post-neoadjuvant trastuzumab emtansine (T-DM1) or trastuzumab (H) in patients (pts) with residual invasive HER2-positive breast cancer (BC) (2019) (11)
- AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update (2021) (11)
- Pre-eclampsia following chemotherapy for breast cancer during pregnancy: case report and review of the literature (2012) (11)
- Trial-level prediction of long-term outcome based on pathologic complete response (pCR) after neoadjuvant chemotherapy for early-stage breast cancer (EBC). (2018) (11)
- Abstract S3-01: IMENEO: International MEta-analysis of circulating tumor cell detection in early breast cancer patients treated by NEOadjuvant chemotherapy (2017) (11)
- Sorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA* (2014) (11)
- Continuous vs intermittent extended adjuvant letrozole for breast cancer: Final results of randomized phase 3 SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy. (2021) (11)
- Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial (2015) (11)
- Exome analysis of oncogenic pathways and tumor mutational burden (TMB) in triple-negative breast cancer (TNBC): Results of the translational biomarker program of the neoadjuvant double-blind placebo controlled GeparNuevo trial. (2019) (11)
- Characteristics and Clinical Outcome of Breast Cancer Patients with Asymptomatic Brain Metastases (2020) (11)
- S3-6: Neoadjuvant Chemotherapy of Paclitaxel with or without Rad001: Results of the Non-Responder Part of the GEPARQUINTO Study (GBG 44). (2011) (11)
- LBA18 Overall survival (os) results from SOLAR-1, a phase III study of alpelisib (ALP) + fulvestrant (FUL) for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) (2020) (11)
- Optimal Systemic Treatment for Early Triple-Negative Breast Cancer. (2020) (10)
- Abstract PD2-07: mRNA signatures predict response to durvalumab therapy in triple negative breast cancer (TNBC)– Results of the translational biomarker programme of the neoadjuvant double-blind placebo controlled GeparNuevo trial (2019) (10)
- Abstract P4-10-04: Clinical outcomes of alpelisib in hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer by next-generation sequencing-detected PIK3CA alteration status and phosphatase and tensin homolog loss: Biomarker analysis from the SOLAR-1 study (2020) (10)
- Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials (2020) (10)
- Correlation of PIK3CA mutation with pathological complete response in primary HER2-positive breast cancer: Combined analysis of 967 patients from three prospective clinical trials. (2015) (10)
- Does toxicity predict efficacy? Insight into the mechanism of action of lapatinib. (2014) (10)
- Prospective, Multicenter, Randomized Phase III Trial Evaluating the Impact of Lymphoscintigraphy as Part of Sentinel Node Biopsy in Early Breast Cancer: SenSzi (GBG80) Trial. (2019) (10)
- Chemotherapy-induced ovarian failure in young women with early breast cancer: Prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trials. (2021) (10)
- PARP expression in early breast cancer and its predictive value for response to neoadjuvant chemotherapy. (2010) (10)
- Abstract OT3-3-11: A RANDOMIZED PHASE III TRIAL COMPARING NANOPARTICLE-BASED PACLITAXEL WITH SOLVENT-BASED PACLITAXEL AS PART OF NEOADJUVANT CHEMOTHERAPY FOR PATIENTS WITH EARLY BREAST CANCER (GeparSepto) GBG 69 (2012) (9)
- Gene Expression–Based Prediction of Neoadjuvant Chemotherapy Response in Early Breast Cancer: Results of the Prospective Multicenter EXPRESSION Trial (2021) (9)
- Abstract GS4-01: Pooled analysis of five randomized trials investigating temporary ovarian suppression with gonadotropin-releasing hormone analogs during chemotherapy as a strategy to preserve ovarian function and fertility in premenopausal early breast cancer patients (2018) (9)
- Model-based optimization of G-CSF treatment during cytotoxic chemotherapy (2017) (9)
- pCR rates in patients with bilateral breast cancer after neoadjuvant anthracycline-taxane based-chemotherapy - A retrospective pooled analysis of individual patients data of four German neoadjuvant trials. (2017) (9)
- 215TiPPALLAS: PALbociclib CoLlaborative adjuvant study: A randomized phase 3 trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for HR+/HER2- early breast cancer (2017) (9)
- Palbociclib (PAL) in combination with fulvestrant (F) in pre-/peri-menopausal (PreM) women with metastatic breast cancer (MBC) and prior progression on endocrine therapy – results from Paloma-3. (2016) (9)
- Abstract P2-08-01: Factors predicting relapse in early breast cancer patients with a pathological complete response after neoadjuvant therapy – Results of a pooled analysis based on the GBG meta-database (2019) (9)
- Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Analyses from PALOMA-3. (2018) (9)
- 350TiP A phase III trial of capivasertib and fulvestrant versus placebo and fulvestrant in patients with HR+/HER2− breast cancer (CAPItello-291) (2020) (9)
- Abstract OT1-1-06: A phase 3, randomized, open-label trial comparing trastuzumab emtansine and trastuzumab as adjuvant therapy for HER2-positive primary breast cancer with residual invasive tumor in the breast or axillary lymph nodes following preoperative therapy (KATHERINE) (2013) (9)
- Updated results of tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB). (2021) (9)
- Abstract CT142: Prevalence ofPIK3CAmutations in patients with hormone receptor-positive, human epidermal growth factor-2-negative advanced breast cancer from the SOLAR-1 trial (2019) (9)
- Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor (2018) (9)
- Breast cancer, locally advanced and metastatic (2012) (9)
- Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial (2019) (9)
- Central review of radiation therapy planning among patients with breast-conserving surgery: results from a quality assurance process integrated into the INSEMA trial. (2020) (9)
- A survey on physicians’ knowledge, practice and attitudes on fertility and pregnancy issues in young breast cancer patients (2017) (9)
- Impact in delay of starting chemotherapy and surgery on pCR/survival in breast cancer (BC)-pooled analysis of individual patient data from six prospectively randomized neoadjuvant trials (2017) (9)
- A phase 3 study of alpelisib (ALP) plus fulvestrant (FUL) in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) ABC progressing on or after aromatase inhibitor (AI) therapy: SOLAR-1. (2017) (8)
- Expression of immunologic genes in triple-negative and HER2-positive breast cancer in the neoadjuvant GEPARSIXTO trial: Prediction of response to carboplatin-based chemotherapy. (2014) (8)
- Impact of treatment characteristics on response of different breast cancer subtypes: Pooled multilayer analysis of the German neoadjuvant chemotherapy trials. (2010) (8)
- Gonadotropin-releasing hormone analogue for premenopausal women with breast cancer. (2011) (8)
- Prognostic and predictive impact of Ki-67 before and after neoadjuvant chemotherapy on PCR and survival: Results of the GeparTrio trial. (2012) (8)
- [Reproduction after breast cancer: what advice do we have for our patients?]. (2005) (8)
- Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast (2021) (8)
- Genomic markers of early progression on fulvestrant with or without palbociclib for ER+ advanced breast cancer in the PALOMA-3 trial. (2019) (8)
- 328TiP Phase III study of trastuzumab deruxtecan (T-DXd) with or without pertuzumab vs a taxane, trastuzumab and pertuzumab in first-line (1L), human epidermal growth factor receptor 2–positive (HER2+) metastatic breast cancer (mBC): DESTINY-Breast09 (2021) (8)
- Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial (2022) (8)
- Epirubicin/paclitaxel/carboplatin (TEC) vs paclitaxel/carboplatin (TC) in first-line treatment of ovarian cancer (OC) FIGO stages IIB-IV. An AGO-GINECO Intergroup phase III trial. (2004) (7)
- Clinical Relevance of Collagen Protein Degradation Markers C3M and C4M in the Serum of Breast Cancer Patients Treated with Neoadjuvant Therapy in the GeparQuinto Trial (2019) (7)
- A phase I dose escalation and pharmacokinetic study of BIBF 1120 in combination with paclitaxel and carboplatin in patients with advanced gynecological malignancies (2007) (7)
- Phase III study evaluating safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy in subjects with early-stage triple-negative breast cancer (TNBC). (2014) (7)
- Ki 67 measured after neoadjuvant chemotherapy for primary breast cancer (2013) (7)
- The AURORA pilot study for molecular screening of patients with advanced breast cancer–a study of the breast international group (2017) (7)
- The GISS Trial: a Phase II Prevention Trial of Screening Plus Goserelin, Ibandronate, versus Screening Alone in Premenopausal Women at Increased Risk of Breast Cancer (2011) (7)
- Effects of capecitabine as part of neo-/adjuvant chemotherapy - A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients. (2022) (7)
- Assessment of Ovarian Function in Phase 3 (Neo)adjuvant Breast Cancer Clinical Trials: A Systematic Evaluation. (2021) (7)
- The rise of oncology biosimilars: from process to promise. (2019) (7)
- Abstract S4-5: Ki67 levels in pretherapeutic core biopsies as predictive and prognostic parameters in the neoadjuvant GeparTrio trial (2012) (7)
- Adjuvant therapy in patients with breast cancer during pregnancy. (2009) (7)
- 10PComparison of the mutational landscape of breast cancer during pregnancy and non-pregnant controls (2017) (7)
- Clinical usefulness and relevance of intermediate endpoints for cytotoxic neoadjuvant therapy. (2015) (7)
- Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis (2022) (7)
- SOLE (Study of Letrozole Extension): A phase III randomized clinical trial of continuous vs intermittent letrozole in postmenopausal women who have received 4-6 years of adjuvant endocrine therapy for lymph node-positive, early breast cancer (BC). (2017) (7)
- CDK4/6 inhibitors in breast cancer: one more step towards reduced mortality. (2019) (6)
- Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancer (2020) (6)
- Abstract GS3-01: Investigating denosumab as an add-on treatment to neoadjuvant chemotherapy and two different nab-paclitaxel schedules in a 2x2 design in primary breast cancer - First results of the GeparX study (2020) (6)
- Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials (2020) (6)
- Abstract 4699: Responsecharacteristics and overall survival of 781 patients with triple-negativebreast cancer - a meta-analysis on 7 German neoadjuvant studies. (2013) (6)
- mdm2 gene amplification is associated with luminal breast cancer progression in humanized PDX mice and a worse outcome of estrogen receptor positive disease (2021) (6)
- A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial (2020) (6)
- Brain Metastases in Breast Cancer Network Germany (BMBC; GBG 79): Multicentric, retro- and prospective collection of patient data and biomaterial from patients with brain metastases. (2015) (6)
- Adjuvant hormone therapy following primary therapy for endometrial cancer. (2002) (6)
- Paclitaxel‐carboplatin‐gemcitabine (TCG) as first‐line treatment of ovarian cancer: a prospective multicenter phase II study (AGO‐OVAR 8) followed by a prospectively randomized phase III GCIG Intergroup study (AGO‐OVAR 9, GINECO‐TCG, NSGO‐OC‐0102) comparing TCG with standard TC (2005) (6)
- Immunophenotype and proliferation to predict for response to neoadjuvant chemotherapy in TNBC: Results from BrighTNess phase III study. (2019) (6)
- Utility of the CPS+EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy (2019) (6)
- Phase III postneoadjuvant study evaluating sacituzumab govitecan, an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA. (2021) (6)
- 499 Breast cancer during pregnancy – a prospective and retrospective European registry (GBG-20/BIG02-03) (2008) (6)
- Outcomes in patients (pts) aged ≥65 years in the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC). (2021) (6)
- 313 Patients with breast cancer during pregnancy – a prospective and retrospective registry (GBG-20 / BIG02-03) (2010) (6)
- Phase I dose finding study evaluating the combination of bendamustine with weekly paclitaxel in patients with pre-treated metastatic breast cancer: RiTa trial (2009) (6)
- EGF-R and Her2/neu overexpressing tumors: independent collectives for treatment of breast cancer by specific monoclonal antibody-therapy (2003) (6)
- Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer: Critical Analysis of Strengths, Weaknesses, and Misinterpretations. (2022) (6)
- German Adjuvant Intergroup Node Positive (GAIN) study: A phase III trial to compare IDD-ETC versus EC-TX in patients with node-positive primary breast cancer—Final efficacy analysis. (2014) (6)
- Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy. (2021) (6)
- Abstract PD7-10: Male-GBG54: A prospective, randomised multi-centre phase II study evaluating endocrine treatment with either tamoxifen +/- gonadotropin releasing hormone analogue (GnRHa) or an aromatase inhibitor + GnRHa in male breast cancer patients (2018) (6)
- Clonidine vs. venlafaxine as treatment for hot flashes in breast cancer patients: A double-blind randomised study (2005) (6)
- Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness (2021) (6)
- Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus (2021) (5)
- Abstract P1-09-02: Homologous repair deficiency (HRD) as measure to predict the effect of carboplatin on survival in the neoadjuvant phase II trial GeparSixto in triple-negative early breast cancer (2017) (5)
- Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial. (2022) (5)
- Systematic analysis of parameters predicting pathological axillary status (ypN0 vs. ypN+) in patients with breast cancer converting from cN+ to ycN0 through primary systemic therapy (PST) (2018) (5)
- Neoadjuvant Clinical Trials for the Treatment of Primary Breast Cancer: The Experience of the German Study Groups (2012) (5)
- Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy. (2021) (5)
- AGO Algorithms for the Treatment of Breast Cancer: Update 2021 (2021) (5)
- Safety, tolerability and activity of gefitinib (ZD1839) in combination with tamoxifen in ovarian cancer patients refractory to platinum-taxane based therapy – a Phase-II study of the Ovarian Cancer Study Group (AGO Ovar 2.6) (2004) (5)
- Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: Results from the phase III BrighTNess trial. (2020) (5)
- Bendamustine in Metastatic Breast Cancer: An Old Drug in New Design (2008) (5)
- A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer. (2021) (5)
- Abstract OT2-02-01: Comparison of axillary sentinel lymph node biopsy versus no axillary surgery in patients with early-stage invasive breast cancer and breast-conserving surgery: A randomized prospective surgical trial. The intergroup-sentinel-mamma (INSEMA)-trial (2016) (5)
- Abstract P6-14-05: Final Overall Survival Analysis of the TBP Phase III Study (GBG 26/BIG 3-05): Capecitabine vs. Capecitabine + Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing during Trastuzumab Treatment (2010) (5)
- An Overview of Clinical Development of Agents for Metastatic or Advanced Breast Cancer Without ERBB2 Amplification (HER2-Low). (2022) (5)
- Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer (2021) (5)
- Survival benefit from response-guided approach: a direct effect of more effective cytotoxic regimens or an indirect effect of chemotherapy-induced amenorrhea? Reply to K.-D. Yu et al. (2014) (5)
- Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer. (2022) (5)
- 4003 ICE Study: A prospective, multi-centre, controlled, open-label, randomized phase III trial of ibandronate (I) with or without capecitabine (X) in elderly patients (pts) with early breast cancer (GBG 32) (2009) (5)
- Factors predicting relapse in early breast cancer patients with a pathological complete response after neoadjuvant therapy: Pooled analysis based on the GBG database. (2019) (5)
- 2O Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): Analysis of the GeparSixto randomized clinical trial (2021) (5)
- How Much Information Do We Really Need After Neoadjuvant Therapy for Breast Cancer? (2017) (5)
- Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor–positive Early Breast Cancer: Results from the SOLE Trial (2020) (5)
- Abstract OT-03-01: Trastuzumab deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual invasive early breast cancer after neoadjuvant therapy: A randomized, phase 3 trial (DESTINY-Breast05) (2021) (5)
- Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial (2019) (5)
- Abstract PD5-08: Tumor immune-cell activity assessed by RNAseq is an independent predictor of therapy response and prognosis after neoadjuvant chemotherapy in HER2 negative breast cancer patients - An analysis of the GeparSepto trial (2020) (5)
- Randomized surgical multicenter trial to evaluate the usefulness of lymphoscintigraphy (LSG) prior to sentinel node biopsy (SLNB) in early breast cancer: SenSzi (GBG80) trial. (2017) (5)
- 0157 GAIN study: A phase III trial to compare ETC vs. EC-TX and ibandronate vs. observation in patients with node-positive primary breast cancer (2009) (5)
- Abstract P4-08-26: Validation of different prognostic scores in breast cancer patients with brain metastases of the BMBC registry (GBG-79) (2019) (4)
- Sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (pts) with previously treated, metastatic triple-negative breast cancer (mTNBC): Final results from the phase 3 ASCENT study. (2022) (4)
- Patient-reported outcomes (PROs) from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer. (2019) (4)
- Dual Blockade of HER-2 Provides a Greater Magnitude of Benefit in Patients With Hormone-Negative Versus Hormone-Positive Breast Cancer. (2016) (4)
- PD07-05: Local Recurrence Risk in 6377 Patients with Early Breast Cancer Receiving Neoadjuvant Anthracycline-Taxane +/− Trastuzumab Containing Chemotherapy. (2011) (4)
- FINESSE: An open, three-cohort, phase II trial testing oral administration of lucitanib in patients with FGFR1-amplified or nonamplified estrogen receptor-positive metastatic breast cancer. (2014) (4)
- AGO Recommendations for the Surgical Therapy of Breast Cancer: Update 2022 (2022) (4)
- Evolution of adjuvant chemotherapy for breast cancer (2015) (4)
- 266PD_PRSENTINEL LYMPH NODE BIOPSY FOR BREAST CANCER TREATMENT DURING PREGNANCY - ON BEHALF OF THE INTERNATIONAL NETWORK OF CANCER, INFERTILITY AND PREGNANCY (INCIP) AND THE GERMAN BREAST GROUP (GBG) (2014) (4)
- GeparDouze/NSABP B-59: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo in patients with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo. (2019) (4)
- Comparison of an automated cartridge-based system for mRNA assessment with central immunohistochemistry in the neoadjuvant GeparX trial. (2019) (4)
- Abstract GS3-04: GS3-04 Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the Phase III CAPItello-291 trial (2023) (4)
- 293P Impact of tucatinib on progression free survival in patients with HER2+ metastatic breast cancer and stable or active brain metastases (2020) (4)
- Abstract OT1-03-21: PALLAS: PAlbociclib Collaborative Adjuvant Study: A randomized phase 3 trial of palbociclib with adjuvant endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer (2016) (4)
- Predicting Prognosis of Breast Cancer Patients with Brain Metastases in the BMBC Registry—Comparison of Three Different GPA Prognostic Scores (2020) (4)
- Validation of a Nomogram Predicting Non-Sentinel Lymph Node Metastases among Patients with Breast Cancer after Primary Systemic Therapy - a transSENTINA Substudy (2018) (4)
- [PTHrP and bone sialoprotein as prognostic markers for developing bone metastases in breast cancer patients]. (2006) (4)
- A phase III, multicenter, double-blind, randomized trial of celecoxib versus placebo in primary breast cancer patients: Randomized European Celecoxib Trial (REACT). (2011) (4)
- Abstract OT3-2-10: Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of fulvestrant with or without PD-0332991 (palbociclib) ± goserelin in women with hormone receptor-positive, HER2-negative metastatic breast cancer (MBC) whose disease progressed after prior endocrine therapy (2013) (4)
- Dose-intensified epirubicin versus standard-dose epirubicin/cyclophosphamide followed by CMF in breast cancer patients with 10 or more positive lymph nodes: results of a randomised trial (GABG-IV E-93) - the German Adjuvant Breast Cancer Group. (2010) (4)
- Combination therapy with pegylated liposomal doxorubicin and carboplatin in malignant gynecologic tumors. A prospective multicenter phase II trial of the AGO-OVAR and the AGO Kommission Uterus (AGO-K-Ut). (2006) (4)
- Capecitabine given concomitantly or in sequence with EC → docetaxel as neoadjuvant treatment for early breast cancer: GeparQuattro – a GBG/AGO intergroup-study (2008) (4)
- Abstract OT1-03-03: FINESSE - An open, 3-cohort, phase II trial testing oral administration of lucitanib in patients with FGFR1-amplified or non-amplIfied oestrogeN rEceptor poSitive metaStatic breast cancEr (2016) (4)
- Abstract PS11-09: Impact ofUGT1A1status on the safety profile of sacituzumab govitecan in the phase 3 ASCENT study in patients with metastatic triple-negative breast cancer (2021) (4)
- Targeting the Immune System in Breast Cancer: Hype or Hope?: TILs and Newer Immune-Based Therapies Being Evaluated for HER2+ and TNBC (2015) (4)
- Neoadjuvant chemotherapy for patients with breast cancer during pregnancy (BCP). (2014) (4)
- Alpelisib (ALP) + fulvestrant (FUL) for patients with hormone receptor–positive (HR+), HER2− advanced breast cancer (ABC): Management and time course of key adverse events of special interest (AESIs) in SOLAR-1 (2019) (4)
- 217OA gene signature of chemo-immunization to predict outcome in patients with triple negative breast cancer treated with anthracycline-based neoadjuvant chemotherapy (2017) (4)
- Predictive markers of response to neoadjuvant durvalumab with nab-paclitaxel and dose dense doxorubicin/cyclophosphamide in basal-like triple negative breast cancer. (2022) (4)
- The EUSOMA recommendations for the management of young women with breast cancer (2012) (4)
- Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer (2022) (4)
- MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial (2020) (4)
- Toxicity in elderly breast cancer patients treated by a taxane based chemotherapy as adjuvant or neoadjuvant therapy for primary breast cancer. (2006) (4)
- 355TiP Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P) + fulvestrant (F) in patients (pts) with PIK3CA-mutant/hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer (HR+/HER2– LA/MBC) (2020) (4)
- E10. Breast cancer during pregnancy (2004) (3)
- Chemotherapy for 70-Year-Old Women with Breast Cancer in Germany: A Survey by the German Breast Group. (2013) (3)
- Evaluating the impact of relative total dose intensity (RTDI) on patient's short- and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer: A pooled analysis. (2009) (3)
- Outcome of breast cancer patients treated with chemotherapy during pregnancy compared with non-pregnant controls. (2021) (3)
- A randomized phase III study to determine the efficacy of capecitabine in addition to a taxane and bevacizumab as first-line therapy in patients with metastatic breast cancer. (2013) (3)
- Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al. (2017) (3)
- Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer. (2022) (3)
- 1801 Neoadjuvant chemotherapy with trastuzumab or lapatinib: Survival analysis of the HER2-positive cohort of the GeparQuinto study (GBG 44) (2015) (3)
- PANTHER: Prospective randomized phase III trial of tailored and dose-dense versus standard tri-weekly adjuvant chemotherapy for high-risk breast cancer in the modern era of endocrine and anti-HER2 therapy. (2016) (3)
- 5002 MoniCa: A multicenter phase II study to determine the efficacy of capecitabine as first line monochemotherapy in patients with HER2 negative, medium-risk, metastatic breast cancer (GBG39) (2009) (3)
- Abstract PD8-02: Residual axillary involvement in early breast cancer in patients with positive sentinel nodes after neoadjuvant chemotherapy (NACT) (2019) (3)
- Alpelisib (ALP) with fulvestrant (FUL) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Primary or secondary resistance to prior endocrine therapy (ET) in the SOLAR-1 trial. (2019) (3)
- Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes (2014) (3)
- Tailored dose-dense chemotherapy in combination with trastuzumab as adjuvant therapy for HER2-positive breast cancer: A secondary analysis of the phase III PANTHER trial. (2019) (3)
- Malignancies in Pregnancy 2 Breast cancer in pregnancy (2012) (3)
- Impact of Nuclear Oestrogen Receptor Beta Expression in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy (2019) (3)
- Phase I/II trial of the anti-idiotypic monoclonal antibody ACA125 in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer (2005) (3)
- Abstract P5-16-01: A randomised phase III trial comparing two dose-dense, dose-intensified approaches (ETC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto) (2017) (3)
- Reply to L. Del Mastro and Z. Blumenfeld (2011) (3)
- Final analysis of the Male-GBG54 study: A prospective, randomised multi-centre phase II study evaluating endocrine treatment with either tamoxifen +/- gonadotropin releasing hormone analogue (GnRHa) or an aromatase inhibitor + GnRHa in male breast cancer patients. (2018) (3)
- Abstract OT2-04-08: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo: NSABP B-59/GBG 96-GeparDouze (2020) (3)
- Abstract PD06-01: Automated computational Ki67 scoring in the GeparTrio breast cancer study cohort (2012) (3)
- Patient-reported outcomes for the Intergroup Sentinel Mamma study (INSEMA): A randomised trial with persistent impact of axillary surgery on arm and breast symptoms in patients with early breast cancer (2022) (3)
- Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2). (2021) (3)
- Abstract GS1-01: Tucatinib vs placebo, both combined with capecitabine and trastuzumab, for patients with pretreated HER2-positive metastatic breast cancer with and without brain metastases (HER2CLIMB) (2020) (3)
- Geparquinto: First Planned Safety Analysis on 60 Patients with HER2 Negative Primary Breast Cancer Receiving Neoadjuvant Chemotherapy ± Bevacizumab or ± RAD001 (GBG 44). (2009) (3)
- Abstract PD2-06: Clinical outcomes of alpelisib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer withPIK3CAalterations detected in plasma ctDNA by next-generation sequencing: Biomarker analysis from the SOLAR-1 study (2021) (3)
- What can be learned from trials running short of patients or events? (2012) (3)
- Impact of palbociclib plus fulvestrant on patient reported general health status compared with fulvestrant alone in HR + , HER2- metastatic breast cancer (2016) (3)
- Breast cancer diagnosed in the post-weaning period is indicative for a poor outcome. (2021) (3)
- Residual Axillary Burden After Neoadjuvant Chemotherapy (NACT) in Early Breast Cancer in Patients with a priori Clinically Occult Nodal Metastases – a transSENTINA Analysis (2020) (3)
- 39 Topotecan versus treosulfan in recurrent ovarian cancer after initial chemotherapy with platinum and paclitaxel. a prospective randomised phase III study of the AGO ovarian cancer study group (2003) (3)
- A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapy (2021) (3)
- Present Status of Adjuvant Chemotherapy for Elderly Breast Cancer Patients (2012) (3)
- Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases (2022) (3)
- A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy (SOLAR-1) (2016) (3)
- Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial. (2022) (3)
- P1-14-05: Surgical Complications from the GeparQuinto Trial of Patients Receiving Preoperative Bevacizumab. (2011) (3)
- Germline mutation status and therapy response in high-risk early breast cancer: Results of the GeparOcto study (NCT02125344). (2019) (3)
- Darbepoetin alfa as primary prophylaxis of anemia in patients with breast cancer treated preoperatively with docetaxel/doxorubicin/cyclophosphamide. (2006) (3)
- Neo-/adjuvant phase III trial to compare intense dose-dense (idd) treatment with EnPC to tailored dose-dense (dt) therapy with dtEC-dtD for patients with high-risk early breast cancer: Results on pathological complete response (pCR) for patients treated within the neoadjuvant setting. (2018) (3)
- HER2-low-positive breast cancer from four neoadjuvant clinical trials - Authors' reply. (2021) (3)
- Abstract PD2-2: Body mass index (BMI) and treatment outcome of breast cancer patients receiving neoadjuvant therapy (NACT) (2013) (3)
- 4016 Quality of life (QoL) in elderly patients (pts) with early-stage breast cancer treated with ibandronate (I) with or without capecitabine (X): results of the GBG 32 ICE trial (2009) (3)
- Phase I study of ZEN-008 (AN-152), a targeted cytotoxic LHRH analog, in female patients with cancers expressing LHRH receptors. (2006) (2)
- Employment or Leadership Position: None Consultant or Advisory Role: None Stock Ownership: None Honoraria: Gunter von Minckwitz, (2009) (2)
- Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE (2022) (2)
- Impact of body mass index on treatment and outcomes in patients with early hormone receptor-positive breast cancer receiving endocrine therapy with or without palbociclib in the PALLAS trial. (2022) (2)
- Assessment of sacituzumab govitecan (SG) in patients with prior neoadjuvant/adjuvant chemotherapy in the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC). (2021) (2)
- Biomarkers for response to immunotherapy in triple-negative breast cancer: Differences between survival and pCR biomarkers. (2022) (2)
- Validated 3 Gene Signature Predicts Response to Neo-Adjuvant Chemotherapy in Luminal Breast Cancer – Results from GeparTrio and GeparQuattro. (2009) (2)
- 8O_PR MUCIN-1 Protein and Mrna Expression in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy (2012) (2)
- 168MO GeparX: Denosumab (Dmab) as add-on to different regimen of nab-paclitaxel (nP)-anthracycline based neoadjuvant chemotherapy (NACT) in early breast cancer (BC): Subgroup analyses by RANK expression and HR status (2020) (2)
- A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC) (2016) (2)
- Chemotherapy-induced ovarian failure (CIOF) in young women with early breast cancer (EBC). (2017) (2)
- Male-GBG54 : a prospective, randomised multi-centre phase II study evaluating endocrine treatment with either tamoxifen plus /- gonadotropin releasing hormone analogue (GnRHa) or an aromatase inhibitor plus GnRHa in male breast cancer patients (2018) (2)
- Abstract OT3-05-08: PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase 3 trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for HR+/HER2- early breast cancer (2018) (2)
- Opinions on the ASCO 2011 Annual Meeting (2011) (2)
- Corrections to "PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab". (2019) (2)
- Abstract OT2-04-02: Comparison of axillary sentinel lymph node biopsy versus no axillary surgery in patients with early-stage invasive breast cancer and breast-conserving surgery: A randomized prospective surgical trial. The Intergroup-Sentinel-Mamma (INSEMA)-trial (2017) (2)
- Physical activity, sedentary time and breast cancer risk: a Mendelian randomisation study (2022) (2)
- Abstract PD5-7: PTEN andPIK3CAbut not p4EBP1 are associated with low rates of pathological complete response (pCR) to trastuzumab based chemotherapy in primary HER2-overexpressing breast cancer (2015) (2)
- Abstract P6-17-08: Brain metastases in breast cancer network Germany (BMBC, GBG 79): First analysis of 548 patients from the multicenter registry (2016) (2)
- P1-06-26: The EndoPredict Score Is a Response Predictor for Neoadjuvant Chemotherapy in ER-Positive, HER2−Negative Breast Cancer. (2011) (2)
- Signatures of mutational processes and response to neoadjuvant chemotherapy in breast cancer: A genome-based investigation in the neoadjuvant GeparSepto trial. (2018) (2)
- Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma (2017) (2)
- Abstract P1-13-05: GAIN-2: Adjuvant phase III trial to compare intense dose-dense (idd) treatment with EnPC to tailored dose-dense (dt) therapy with dtEC-dtD for patients with high-risk early breast cancer: Results of the second safety interim analyses (2016) (2)
- OT3-01-15: Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy as First-Line Treatment for Advanced Breast Cancer: The LEA Study. (2011) (2)
- Paclitaxel-carboplatin-gemcitabine (TCG) as first-line treatment of ovarian cancer: a prospective multicenter phase II study (AGO-OVAR 8) followed by a prospectively randomized phase III GCIG Intergroup study (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102) comparing TCG with standard TC (2005) (2)
- A randomized phase II study to investigate the addition of PD-L1 antibody MEDI4673 (durvalumab) to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (GeparNuevo) (2016) (2)
- Patient-reported outcomes (PROs) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) from SOLAR-1. (2019) (2)
- Investigating denosumab as an add-on neoadjuvant treatment for RANK/L-positive or RANK/L-negative primary breast cancer and two different nab-paclitaxel schedules: 2x2 factorial design (GeparX)—An iterim safety analysis. (2018) (2)
- A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA) (2019) (2)
- Palbociclib combined with endocrine treatment in breast cancer patients with high relapse risk after neoadjuvant chemotherapy: Subgroup analyses of premenopausal patients in PENELOPE-B. (2021) (2)
- Brain Metastases in Breast Cancer Network Germany (BMBC, GBG 79): Treatment patterns and clinical outcome of more than 1000 patients with brain metastases from breast cancer. (2016) (2)
- Reply to A. Morabito et al and G. Valabrega et al (2009) (2)
- Correlation of the tumor mutational burden with the composition of the immune cell subpopulations in peripheral blood of triple-negative breast cancer patients undergoing neoadjuvant therapy with durvalumab: Results from the prospectively randomized GeparNuevo trial. (2019) (2)
- Correction: Phase I clinical study of the recombinant antibody-toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas (2006) (2)
- Lucitanib for the treatment of HR+ HER2- metastatic breast cancer (MBC) patients (pts): Results from the multicohort phase II FINESSE trial. (2018) (2)
- Safety, tolerability and activity of gefitinib (ZD1839) in combination with tamoxifen in ovarian cancer patients refractory to platinum-taxane based therapy - a Phase-II study of the Ovarian Cancer Study Group (AGO Ovar 2.6). (2004) (2)
- Mitomycin-C, 5-FU, Folinic Acid (Mi-Fu-Fo) as salvage chemotherapy for hepatic failure due to liver metastases in breast cancer (2004) (2)
- Everolimus (RAD) as treatment in breast cancer patients with bone metastases only: Results of the phase II RADAR study. (2012) (2)
- Identification of thymosin beta 15 A (TMSB15A) mRNA expression as a predictor for response to neoadjuvant chemotherapy in patients with operable breast cancer. (2010) (2)
- Abstract P5-20-09: Pharmacokinetic results of a subcutaneous injection of trastuzumab into the thigh versus into the abdominal wall in patients with HER2-positive primary breast cancer (BC) treated within the neo-/adjuvant GAIN-2 study (2018) (2)
- Autologous Lipotransfer - Daily Therapeutic Practice in Breast Cancer: An Intergroup Analysis Encompassing NOGGO, WSG, GBG, AWO Gyn and DGPRÄC (2018) (2)
- 160O Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer, TNBC) (PM(Cb)) for patients (pts) with high-risk early breast cancer (BC) (2020) (2)
- Abstract P3-14-01: Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: KATHERINE subgroup analysis (2020) (2)
- GAIN-2: Neo-/adjuvant phase III trial to compare intense dose-dense chemotherapy (CT) to tailored dose-dense CT in patients (pts) with high risk early breast cancer (EBC): Results on safety and interim invasive disease-free survival (iDFS). (2020) (2)
- 176P Germline mutation status and therapy response in patients with homologous recombination deficient, HER2-negative early breast cancer: Results of the GeparOLA study (NCT02789332) (2020) (2)
- AGO-OVAR 14: A retrospective study evaluating the reasons for non-participating in trials in patients with ovarian cancer (OC) treated in coordinating centers of the AGO Ovarian Cancer Study Group. (2004) (2)
- Paclitaxel-carboplatin-gemcitabine (TCG) versus paclitaxel-carboplatin (TC) as first line treatment in women with ovarian cancer: A randomized phase III GCIG Intergroup study (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102) (2006) (2)
- Adjuvant phase III trial to compare intense dose-dense adjuvant treatment with EnPC to dose dense, tailored therapy with dtEC-dtD for patients with high-risk early breast cancer (GAIN-2). (2013) (2)
- Lack of correlation of neoantigens arising from tumor somatic mutations with tumor infiltrating lymphocytes (TILs) or survival in HER2-positive breast cancer (HER2+ BC). (2015) (2)
- Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: Surgical results from an international randomized trial (BrighTNess). (2017) (2)
- Abstract CT055: A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs. placebo in combination with capecitabine (C) and trastuzumab (Tz) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC) (HER2CLIMB) (2017) (2)
- Investigating denosumab as add-on neoadjuvant treatment for hormone receptor-negative, RANK-positive or RANK-negative primary breast cancer and two different nab-Paclitaxel schedules - 2x2 factorial design (GeparX). (2016) (2)
- Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer: Results from the GeparQuattro study (GBG 40). (2011) (2)
- Abstract PD3-01: BluePrint performance in predicting pertuzumab benefit in genomically HER2-positive patients: A biomarker analysis of the APHINITY trial (2021) (2)
- Abstract P1-17-07: Cancer management and outcome of very young non-pregnant patients with breast cancer diagnosed at 40 years or younger– GBG 29 (2019) (2)
- Clinical Experience with Lapatinib in Patients with ErbB2-Overexpressing Metastatic Breast Cancer (2008) (1)
- Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC): Biomarker (BM) analyses by next-generation sequencing (NGS) from the SOLAR-1 study. (2022) (1)
- 0155 ICE study: Ibandronate with or without capecitabine in elderly patients with early breast cancer (2009) (1)
- Response pattern in 844 patients with infiltrating lobular carcinoma (ILC) of the breast after neoadjuvant chemotherapy. (2012) (1)
- 264PDGAIN2: ADJUVANT PHASE III TRIAL COMPARING AN INTENSIFIED DOSE-DENSE ADJUVANT THERAPY WITH ENPC COMPARED WITH A DOSE-DENSE, DOSE-ADAPTED THERAPY WITH DTEC DTDOCETAXEL IN PATIENTS WITH PRIMARY BREAST CANCER AND A HIGH RISK OF RECURRENCE. (2014) (1)
- Abstract P3-06-05: Expression of SPARC in human breast cancer and its predictive value in the GeparTrio neoadjuvant trial. (2012) (1)
- Chemotherapy (CT)-induced anaemia in patients (pts) treated with dose-dense regimen: Results of the prospectively randomised anaemia substudy from the neoadjuvant GeparOcto study (2019) (1)
- Rechallenging taxanes in recurrent breast cancer in patients treated with (neo-) adjuvant taxane-based therapy. (2011) (1)
- Dose tailoring of breast cancer adjuvant chemotherapy aiming at avoiding both over and undertreatment: Results from the prospective PANTHER study. (2018) (1)
- Abstract GS4-04: Ten year results of the international breast cancer intervention study II (2020) (1)
- EPIRUBICIN/PACLITAXEL/CARBOPLATIN (TEC) VERSUS PACLITAXEL/CARBOPLATIN (TC) IN FIRST-LINE TREATMENT OF OVARIAN CANCER FIGO STAGES IIB-IV. MATURE RESULTS OF A RANDOMIZED AGO-GINECO GCIG INTERGROUP PHASE III TRIAL (2004) (1)
- Understanding the barriers to, and facilitators of, ovarian toxicity assessment in breast cancer clinical trials (2022) (1)
- Low TMB as predictor for additional benefit from neoadjuvant immune checkpoint inhibition in triple-negative breast cancer. (2022) (1)
- Abstract OT1-02-09: A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC) (HER2CLIMB) (2017) (1)
- Lapatinib Can Be Safely Given Concomitantly to EC-Doc as Neoadjuvant Chemotherapy for Breast Cancer. First Planned Safety Analysis of the Geparquinto Study (GBG 44). (2009) (1)
- Predictors of efficacy in patients (pts) with hormone receptor–positive/ human epidermal growth factor receptor 2–negative advanced breast cancer (HR+/HER2− ABC): Subgroup analyses of PALOMA-3 (2020) (1)
- Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab (P+T) in the APHINITY trial. (2021) (1)
- Effect of mast cells on efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme b. (2017) (1)
- Prognosis of Women With Primary Breast Cancer Diagnosed During Pregnancy - Reply (2014) (1)
- A randomized phase III trial comparing nanoparticle-based paclitaxel with solvent-based paclitaxel as part of neoadjuvant chemotherapy for patients with early breast cancer (GeparSepto): GBG 69. (2013) (1)
- Abstract OT1-02-03: Trastuzumab deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual invasive early breast cancer after neoadjuvant therapy: A randomized, phase 3 trial (DESTINY-Breast05) (2022) (1)
- Changes in hormone levels (E2, FSH, AMH) and fertility of young women treated with neo-/adjuvant chemotherapy (CT) for early breast cancer (EBC) (2018) (1)
- Abstract P5-06-02: Pathologic complete response (pCR) and prognosis following neoadjuvant chemotherapy plus anti-HER2 therapy of HER2-positive early breast cancer (EBC) (2020) (1)
- The Reawakening of Bendamustine – Also in Breast Cancer? (2009) (1)
- A randomized study of tucatinib (ONT-380) vs. placebo in combination with capecitabine and trastuzumab in patients with pretreated HER2-pos. metastatic breast cancer: HER2CLIMB (2018) (1)
- Germline mutation status and therapy response in patients with triple-negative breast cancer (TNBC): Results of the GeparOcto study. (2018) (1)
- Abstract P3-07-03:PIK3CAmutations predict resistance to trastuzumab/pertuzumab andnab-paclitaxel in primary HER2-positive breast cancer – Massive parallel sequencing analysis of 293 pretherapeutic core biopsies of the GeparSepto study (2016) (1)
- Abstract PD9-04: Immunological and clinical consequences of durvalumab treatment in combination to neoadjuvant chemotherapy in triple-negative breast cancer patients (2023) (1)
- The GISS Trial: A pilot phase randomized prevention trial of screening plus goserelin plus ibandronate, versus screening alone in premenopausal women at high risk of breast cancer (2008) (1)
- Evaluation of neutrophil gelatinase-associated lipocalin (NGAL) as predictor of response to neoadjuvant chemotherapy (NACT) in primary breast cancer. (2011) (1)
- Axillary Staging after Neoadjuvant Chemotherapy for Initially Node-Positive Breast Carcinoma in Germany (2021) (1)
- Abstract P1-17-01: Development of brain metastases in breast cancer patients treated in the neoadjuvant trials Geparquinto and Geparsixto (2018) (1)
- Abstract P2-08-10: Similarities between low hormone receptor positive and hormone receptor negative breast cancer: An analysis of 4366 patients from multicenter clinical trials (2019) (1)
- Abstract OT3-05-01: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo: NSABP B-59/GBG 96-GeparDouze (2019) (1)
- Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon. (2022) (1)
- Advances in the treatment of oestrogen receptor positive advanced breast cancer (2017) (1)
- Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT (2022) (1)
- TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer (2021) (1)
- Abstract 5010: Prediction of therapy resistance by targeted massive-parallel sequencing in primary HER2-positive breast cancer (2016) (1)
- Assessment of ovarian function as an endpoint in breast cancer clinical trials: A systematic review. (2020) (1)
- Abstract PS10-35: Early intervention for and management of alpelisib (ALP)-induced hyperglycemia: Case studies from the phase III SOLAR-1 trial (2021) (1)
- Multicenter Phase II Study with Weekly Bendamustine and Paclitaxel as First- or Later-Line Therapy in Patients with Metastatic Breast Cancer: RiTa II Trial (2011) (1)
- 255ODUAL BLOCKADE WITH AFATINIB AND TRASTUZUMAB AS NEOADJUVANT TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED OR OPERABLE BREAST CANCER RECEIVING TAXANE-ANTHRACYCLINE CONTAINING CHEMOTHERAPY (DAFNE)-GBG70 - EFFICACY AND SAFETY ANALYSIS. (2014) (1)
- Risk factors for locoregional recurrence (LRR) after neoadjuvant chemotherapy: Pooled analysis of prospective neoadjuvant breast cancer (BC) trials (2019) (1)
- The Dual Role of Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Two Sides of the Same Coin? (2015) (1)
- A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab pre-treated patients with Her2-positive metastatic breast cancer - E-Vita - (2016) (1)
- 86P Patients (pts) preference for different administration methods of trastuzumab (T) in pts with HER2+ early breast cancer (BC) treated within the GAIN-2 trial (2020) (1)
- PG 8.01 Primary systemic therapy for clinicians: medical and research perspectives (2015) (1)
- 248TiP A randomized, double-blind, phase III trial of neoadjuvant chemotherapy (NACT) with atezolizumab/placebo in patients (pts) with triple-negative breast cancer (TNBC) followed by adjuvant continuation of atezolizumab/placebo (GeparDouze) (2020) (1)
- Abstract P4-10-01: Quality of life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05) (2022) (1)
- NSABP B-59/GBG 96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in patients (pts) with triple-negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo. (2019) (1)
- Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib (2022) (1)
- Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy (2020) (1)
- Impact of expression levels of mRNA HER2 and ESR1 on the pathologic complete remission (pCR) rate after neoadjuvant treatment with anthracycline-taxane containing chemotherapy in combination with trastuzumab in the GeparQuattro trial. (2012) (1)
- 4265 Pegfilgrastim on day 2 vs. day 4 within the prospective, multi- centered GAIN study: A phase III trial to compare ETC vs. EC-TX and ibandronate vs. observation in patients with node-positive primary breast cancer (GBG 33) (2009) (1)
- SOFIA: Phase II study of neoadjuvant epirubicin, cyclophosphamide (EC) plus sorafenib (S) followed by paclitaxel (Pw) plus sorafenib (S) in women with previously untreated primary breast cancer (BC). (2010) (1)
- Abstract P3-15-02: Underreporting of Myelotoxicity with Emerging Breast Cancer Regimens (2010) (1)
- 5005 ORAL Randomized, multicenter, 2-dose-level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody catumaxomab (anti-EpCAM × anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients (2007) (1)
- Characteristics of patients with brain metastases from HER2-positive breast cancer (2021) (1)
- Abstract P3-06-36: Assessment of phosphorylated HER2 protein as predictive biomarker to stratify anti-HER2 treatment in HER2 non-amplified patients – A translational study in the GeparQuattro and GeparQuinto trials (2015) (1)
- Deciphering clonality in aneuploid breast tumors using SNP array and sequencing data (2014) (1)
- Abstract P6-18-03: Biomarker analysis of CDK 4/6 and endocrine pathways in hormone-receptor positive (HR+) advanced breast cancer (ABC) bone only disease patients: A joint analysis of PALOMA-2 and PALOMA-3 studies (2019) (1)
- Abstract OT2-24-02: ZEST: Randomized phase III study evaluating efficacy and safety of niraparib in patients with HER2-negative BRCA-mutated or triple-negative breast cancer with detectable circulating tumor DNA after definitive therapy (2022) (1)
- Data describing the poor outcome associated with a breast cancer diagnosis in the post-weaning period (2021) (1)
- Cost-effectiveness analysis of VEGF-C: A novel predictive biomarker for response to bevacizumab in the neoadjuvant therapy of early breast cancer patients. (2015) (1)
- Managing Breast Cancer During Pregnancy (2016) (1)
- Abstract PD7-09: Changes in hormone levels (E2, FSH, AMH) and fertility of young women treated with neoadjuvant chemotherapy (CT) for early breast cancer (EBC) (2018) (1)
- 45PCost-effectiveness analysis of VEGF-A testing to predict response to bevacizumab (BEV) as a component of neo-adjuvant therapy of early HER-2 negative breast cancer (2015) (1)
- Abstract LB-069: ESR1 mutations in circulating tumour DNA predict outcome to endocrine treatment in patients with estrogen receptor positive advanced breast cancer; analysis of 521 patients in the SoFEA and PALOMA3 trials (2016) (1)
- [Uterine rupture after uterine perforation during D & C and diagnostic hysteroscopy in a patient with endometrial polyp]. (2003) (1)
- Subgroup of post-neoadjuvant luminal-B tumors assessed by HTG in PENELOPE-B investigating palbociclib in high risk HER2-/HR+ breast cancer with residual disease. (2021) (1)
- Abstract P3-06-12: Predicting residual risk of recurrence after neoadjuvant chemotherapy- a retrospective analysis of EndoPredict® in the GeparTrio trial (2015) (1)
- Abstract OT1-1-13: Dual blockade with Afatinib and Trastuzumab as neooadjuvant treatment for patients with locally advanced or operable breast cancer receiving taxane-anthracycline containing chemotherapy (DAFNE)-GBG70 (2012) (1)
- Local versus central HER2 immunohistochemistry correlates with kinetic RT-PCR but only central immunohistochemistry and RT-PCR predict pathological complete response: results from the neoadjuvant multicenter GeparTrio trial. (2009) (1)
- Integrating CDK 4-6 in the treatment of patients with early breast cancer (2021) (1)
- Response rate by geographic region in patients with hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer from the SOLAR-1 trial. (2019) (1)
- Geparquinto: An interim safety analysis of epirubicin/cyclophosphamide followed by docetaxel with or without bevacizumab as neoadjuvant chemotherapy for primary breast cancer patients. (2016) (1)
- Tamoxifen treatment for male breast cancer and risk of thromboembolism: prospective cohort analysis (2019) (1)
- Prevention Trials in Women at Moderate Risk of Breast Cancer (2006) (1)
- 257OINTENSE DOSE-DENSE EPIRUBICIN (E), PACLITAXEL (T), CYCLOPHOSPHAMIDE (C) (IDDETC) IS HIGHLY EFFECTIVE IN ADJUVANT THERAPY OF NODE-POSITIVE BREAST CANCER PATIENTS (PTS). AN ANALYSIS OF THE GBG, AGO-B, AND NOGGO STUDY GROUPS. (2014) (1)
- Reply to L. Ozretić et al (2011) (1)
- Abstract P1-14-11: nab-paclitaxel at a dose of 125 mg/m2weekly is more efficacious but less toxic than at 150 mg/m2. Results from the neoadjuvant randomized GeparSepto study (GBG 69) (2016) (1)
- Risk assessment after neoadjuvant chemotherapy in luminal breast cancer: A prospectively planned validation of gene expression based and clinical prognostic scores in 428 residual tumor samples from two neoadjuvant clinical trials. (2016) (1)
- Serum carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the GeparQuinto phase III neoadjuvant breast cancer trial. (2016) (1)
- Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history (2018) (1)
- Evaluating the addition of bevacizumab (Bev) to endocrine therapy as first-line treatment for hormone-receptor positive (HR+)/HER2-negative advanced breast cancer (ABC): Pooled-analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials. (2017) (1)
- A gene signature of chemo-immunization to predict outcome in patients with triple negative breast cancer treated with neoadjuvant chemotherapy. (2017) (1)
- 18PBrain Metastases in Breast Cancer Network Germany (BMBC, GBG 79): Multicentric, retrospective and prospective collection of patient data and biomaterial from breast cancer patients as platform for translational research (2015) (1)
- Abstract P2-13-42: Effect of young age at diagnosis on clinical outcomes and efficacy of anti-HER2 targeted therapy in patients with HER2-positive early breast cancer: Results from the APHINITY trial (2022) (1)
- Factors associated with axillary conversion after neoadjuvant chemotherapy (NAT) in initially node positive breast cancer patients – a transSENTINA analysis (2020) (1)
- Reply to F. Bellati et al (2010) (1)
- Cyclin dependent kinase 4/6 inhibitors in early breast cancer: what is the role of Ki-67? (2022) (1)
- Concerning Dediu M, Zielinski A: A Proposal to Redefine Pathologic Complete Remission as Endpoint following Neoadjuvant Chemotherapy in Early Breast Cancer. Breast Care 2019; Doi 10.1159/000500620 (2019) (1)
- Abstract P1-08-25: RANK expression is prognostic and predictive in primary breast carcinoma: Analysis of samples from the GeparTrio study (2013) (1)
- 30PTargeted mRNA sequencing of small formalin-fixed and paraffin-embedded breast cancer samples for the quantification of immune and cancer-related genes (2017) (1)
- The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group (2021) (1)
- The AURORA pilot study for molecular screening of patients with advanced breast cancer–a study of the breast international group (2017) (1)
- [Molecular diagnostic and targeted therapy--"Barking dogs are going to bite": presentations from the 42nd Annual Meeting of the American Society of Clinical Oncology, Atlanta 2006]. (2006) (1)
- Abstract P4-06-01: Immunomonitoring of triple negative breast cancer patients undergoing neoadjuvant therapy with durvalumab - Results from the prospectively randomized GeparNuevo trial (2019) (0)
- Molecular and Cellular Pathobiology Novel Theranostic OpportunitiesOffered byCharacterization of Altered Membrane Lipid Metabolism in Breast Cancer Progression (2011) (0)
- Using ultrasound and palpation for predicting axillary lymph node status following neoadjuvant chemotherapy: Results from the prospective multi-center SENTINA trial. (2016) (0)
- Abstract OT2-2-05: A prospective, randomised multi-centre phase II study evaluating the adjuvant, neoadjuvant or palliative treatment with tamoxifen +/− GnRH analogue versus aromatase inhibitor + GnRH analogue in male breast cancer patients (GBG-54 MALE) (2012) (0)
- The German Breast Group – Healing Through Innovation, Competence and Partnership (2009) (0)
- Mucin-1 protein and mRNA expression in breast cancer: Predictive value for therapy response and survival after neoadjuvant chemotherapy. (2012) (0)
- Reports of Oncological Societies (2014) (0)
- SA 9.2 Optimal systemic therapy for residual disease in TNBC (2023) (0)
- Abstract P4-21-06: Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: A subanalysis of data from the randomized phase III GeparSepto trial (2017) (0)
- Abstract PD9-07: Mdm2 gene amplification in estrogen receptor-positive breast cancer cells is associated with enhanced solid tumor growth and pronounced metastatic potential in humanized tumor mice (HTM) and a poor outcome of patients with luminal breast cancer (2022) (0)
- Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto (2019) (0)
- Influence of PIK3CA mutations on breast cancer proliferation, lymphocyte infiltration and clinical outcome: Pooled analysis of 484 patients from three prospective multicentre GBG trials. (2019) (0)
- Selection of endpoints in breast cancer clinical trials: a qualitative study of key trial stakeholders. (2022) (0)
- Influence of denosumab on disseminated tumor cells (DTC) in the bone marrow of breast cancer (BC) patients with neoadjuvant treatment: A GeparX translational substudy. (2020) (0)
- Abstract PD15-06: PD15-06 Pathologic complete response and breast-conserving surgery are associated with improved prognosis in patients with early-stage triple-negative breast cancer treated with neoadjuvant chemotherapy (2023) (0)
- Investigating Denosumab as an add-on neoadjuvant treatment for RANK/L-positive or RANK/L-negative primary breast cancer and two different nab-Paclitaxel schedules – 2 × 2 factorial design (GeparX) (2018) (0)
- Abstract P4-04-08: Histological and epigenetic analyses of placenta tissue from breast cancer patients and healthy participants (2020) (0)
- Para-necrotic expression of VEGFA metagene signature identified by single-cell profiling. (2019) (0)
- Corrigendum to “Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2–) advanced breast cancer (ABC): Subgroup analysis of 2 randomized phase 3 studies” [Breast 41S1 (2018) S11–12] (2020) (0)
- Intratumoral CD8+ T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer. (2023) (0)
- Abstract PD2-3: High body mass index (BMI) and worse response to neoadjuvant chemotherapy (NACT) by breast cancer phenotype: Own data and external validation on German breast group (GBG) patients (2013) (0)
- Current Perspectives on HER2-Positive BC (2014) (0)
- Reply to the letter to the editor 'Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study' by Daly et al. (2017) (0)
- Breast cancer 2 HER 2-positive breast cancer (2016) (0)
- Targeting the CDK4/6 pathway from research to clinic (2017) (0)
- Abstract OT2-01-03: ELEVATE: A phase 1b/2, open-label, umbrella study evaluating elacestrant in various combinations in women and men with metastatic breast cancer (mBC) (2023) (0)
- 46Pp53 mutations in HER2 positive and triple negative breast cancer treated with neoadjuvant chemotherapy – A translational subproject of the GeparSixto trial (2015) (0)
- Abstract P2-03-09: Comparison of the mutational landscape of breast cancer during pregnancy and non-pregnant controls (2017) (0)
- Abstract P5-10-09: Comparison of the (Non-)Hematological Toxicity and Compliance of Different Anthracycline Containing Regimen with the Standard AC/EC in Elderly Patients with Primary Breast Cancer (2010) (0)
- DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status (2021) (0)
- 39OConstitutively activated STAT3 is predictive for trastuzumab resistance in primary HER2 positive breast cancer (2015) (0)
- 00014 A PHASE II STUDY OF THE AGO OVARIAN CANCER STUDY GROUP (AGO-OVAR 2.6): ZD1839 IN COMBINATION WITH TAMOXIFEN IN REFRACTORY OVARIAN CANCER (2005) (0)
- Abstract P2-09-02: Blinded molecular subtyping analysis from RNA-Seq of FFPE samples in the GeparQuinto trial reveals predictive value of VEGFA metagene for bevacizumab treatment (2018) (0)
- Preeclampsia after chemotherapy for breast cancer during pregnancy–case report and review of the literature (2011) (0)
- Abstract P5-13-36: Germline BRCA1/2 and other predisposition genes in high-risk early-stage HR+/HER2- breast cancer (BC) patients treated with endocrine therapy (ET) with or without palbociclib: A secondary analysis from the PENELOPE-B study (2022) (0)
- Low Positivity for Hormone Receptors in Early Breast Cancer: Therapy-Response and Prognosis -A Systematic Analysis of a Total of 9027 Patients (2019) (0)
- 21P BACH1 and HIF1α predict response to neoadjuvant nab-paclitaxel (nP) treatment in early breast cancer (BC) (2021) (0)
- 12 Monitoring serum HER2 levels in the neoadjuvant “Geparquattro” trial – a decrease predicts pathological complete remission (2010) (0)
- Development and validation of a new prognostic score on 4,646 patients with luminal-like breast cancer (BC) enrolled in 7 randomized prospective trials. (2016) (0)
- Predictive Biomarkers and Personalized Medicine Ki67Measured after Neoadjuvant Chemotherapy for Primary Breast Cancer (2013) (0)
- A randomized, open-label, multicentre, phase IV study evaluating palbociclib plus endocrine treatment versus a chemotherapy based treatment strategy in patients with hormone receptor positive/HER2-negative metastatic breast cancer in a real world setting. (2017) (0)
- Abstract P6-15-03: Outcome after neoadjuvant chemotherapy in elderly breast cancer patients – a pooled analysis of individual patient data from eight prospectively randomized controlled trials (2018) (0)
- Editorial Board / Contents / Imprint (2016) (0)
- Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy (2019) (0)
- Abstract OT3-05-04: A randomized, open-label, multi-center phase IV study evaluating palbociclib plus endocrine treatment versus a chemotherapy-based treatment strategy in patients with hormone receptor-positive, HER2-negative metastatic breast cancer in a real world setting (PADMA) (2018) (0)
- Abstract P2-07-05: A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced stage breast cancer treated with first-line endocrine therapy (2019) (0)
- Abstract P6-16-09: SPARC expression in brain metastases of breast cancer patients (2015) (0)
- Brain Metastases in Breast Cancer Network Germany (BMBC, GBG 79): aktueller Stand und Analyse der Patientendaten des Hirnmetastasenregisters (2016) (0)
- THE ALPELISIB (ALP) EXPERIENCE IN THE SOLAR-1 AND BYLIEVE STUDIES: PERSPECTIVES FOR PRACTITIONERS CARING FOR PATIENTS (PTS) WITH HORMONE RECEPTOR-POSITIVE (HR+), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2–) ADVANCED BREAST CANCER (ABC) (2021) (0)
- A randomized, double-blind, phase III trial of neoadjuvant chemotherapy with Atezolizumab/Placebo in patients with triple-negative breast cancer followed by adjuvant continuation of Atezolizumab/Placebo (GeparDouze) (2018) (0)
- 316TiPBREAKOUT: A cross-sectional, prospective, observational study of germline BRCA mutation (gBRCAm) prevalence and real-world outcomes among patients (pts) with HER2-negative (HER2-ve) metastatic breast cancer (mBC) (2017) (0)
- Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer. (2023) (0)
- Abstract P5-16-01: Assessment of health-related quality of life by clinical response from the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC) (2022) (0)
- A phase I study of nab-paclitaxel in patients (pts) with advanced solid tumors and hepatic dysfunction (2008) (0)
- Abstract OT2-5-01: Brain metastases in breast cancer network Germany (BMBC, GBG 79): Multicentric, retro- and prospective collection of patient data and biomaterial from breast cancer patients with brain metastases (2015) (0)
- Abstract P3-13-06: Development and validation of a nomogram predicting pathological axillary status (ypN0 vs. ypN+) in a subgroup of patients converting from cN+ to ycN0 through neoadjuvant therapy (NAT) – A transSENTINA substudy (2017) (0)
- KATHERINE: Trastuzumab emtansine vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer (2019) (0)
- AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022. (2022) (0)
- Management of the axilla for high-risk early breast cancer (EBC) before and after neoadjuvant chemotherapy (NACT): an analysis of the multicentre GeparOcto trial (2020) (0)
- Abstract P6-10-03: Germline(g)BRCA1/2mutations (m) and hematological toxicities in patients (pts) with triple negative breast cancer (TNBC) treated with neoadjuvant chemotherapy (NACT) (2020) (0)
- Pharmacodynamics of sorafenib: An exploratory assessment of circulating biomarkers in a phase II metastatic breast cancer trial (2007) (0)
- SA 11.1 Post-menopausal: Who needs chemotherapy in the neo (adjuvant) setting? (2023) (0)
- Editorial Board / Contents / Imprint (2016) (0)
- Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial (2019) (0)
- Abstract P6-15-01: Withdrawn (2018) (0)
- Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER 1 Advanced Breast Cancer (2021) (0)
- Abstract OT1-03-08: DESIREE - A multicenter, randomized, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (2016) (0)
- Abstract OT-36-01: Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P) + fulvestrant (F) in patients withPIK3CA-mutant/hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer (HR+/HER2- LA/MBC) (2021) (0)
- ' s response to reviews Title : Gross cystic disease fluid protein 15 ( GCDFP-15 ) expression in breast cancer subtypes (2014) (0)
- Abstract P2-11-04: Efficacy and safety of darbepoetin alfa or epoetin beta in 2994 high risk early breast cancer patients participating in the German adjuvant intergroup node-positive study (GAIN) (2017) (0)
- A Phase III, Randomized, Multicenter, Double-blind Study to Compare Efficacy and Safety of EG12014 (EirGenix Trastuzumab) with Herceptin® as Neoadjuvant Treatment in Combination with Anthracycline/Paclitaxel-based Systemic Therapy in Patients with HER2-positive Early Breast Cancer (2022) (0)
- [San Antonio Breast Cancer Symposium -- highlights 2004]. (2005) (0)
- Abstract P5-16-15: Post-progression therapy outcomes in patients (pts) from the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC) (2022) (0)
- Contents Vol. 6, 2011 (2011) (0)
- Abstract ES2-2: Neoadjuvant therapy in HER2 positive breast cancer, latest developments and biomarkers and how it serves as a discovery platform (2015) (0)
- Abstract P5-17-01: A definition of a high-risk early-breast cancer population based on data from the collaborative trials in neoadjuvant breast cancer (CTNeoBC) meta-analysis (2013) (0)
- Prediction of occult axillary metastases in treatment-naïve patients with breast cancer – a transSENTINA analysis (2019) (0)
- Abstract P1-14-01: Adding capecitabine and trastuzumab to neoadjuvant breast cancer chemotherapy - first survival analysis of the GBG/AGO intergroup-study GeparQuattro. (2012) (0)
- Impact of menopause status on breast cancer outcomes and amenorrhea incidence during adjuvant tailored dose dense chemotherapy (2019) (0)
- Abstract 1220:PIK3CAmutations in primary HER2-positive and triple negative breast cancer. (2013) (0)
- Editorial Board / Contents / Imprint (2015) (0)
- 11 Everolimus (Rad001) as Treatment in Breast Cancer Patients with Bone Metastases Only – First Results of the Multi-centre, Placebo-controlled, Randomized Discontinuation Phase II RADAR Study (2012) (0)
- Abstract PS10-01: 6-year absolute invasive disease-free survival (IDFS) benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A STEPP analysis of the APHINITY (BIG 4-11) trial (2021) (0)
- Abstract P4-04-14: Immunological markers in patients with breast cancer occurring during pregnancy - Results from GBG BCP study (2022) (0)
- Abstract P3-07-28: BRCA1-like profile as predictive biomarker in non myeloablative chemotherapy (GAIN study) (2016) (0)
- 196 Managing adverse effects of treatment – Fertility (2012) (0)
- Operable Breast Cancer: Neoadjuvant Treatment (Methodology) (2008) (0)
- Young women and fertility in breast cancer (2008) (0)
- Abstract PD17-05: Development and Validation of a Composite Biomarker Predictive of Palbociclib + Endocrine Treatment Benefit in Early Breast Cancer: PENELOPE-B and PALLAS Trials (2023) (0)
- Incorporating Agents that Target HER2 in the Neoadjuvant Setting (2011) (0)
- 322P Prognostic factors for overall survival (OS) in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (HR+/HER2− ABC): Analyses from PALOMA-3 (2020) (0)
- 21PExpression of CD138 / syndecan-1 in triple-negative breast cancer – correlative study of GeparSixto (2015) (0)
- First-in-Class-Therapie mit Sacituzumab Govitecan (2022) (0)
- Randomized, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal b/HER2 normal breast cancer (GENEVIEVE). (2013) (0)
- Abstract PD4-02: PD4-02 Spatial and temporal heterogeneity of predictive and prognostic signatures in triple-negative breast cancer treated with neoadjuvant combination immune-chemotherapy (2023) (0)
- 111 SOFIA: phase II study of neoadjuvant epirubicin, cyclo-phosphamide (EC) + sorafenib (S) followed by paclitaxel (Pw) + sorafenib (S) in women with previously untreated primary breast cancer (BC) (GBG 45) (2010) (0)
- Abstract P1-20-02: Axillary conversion rates according to breast cancer subtype among patients with pathological complete remission (pCR) in the breast after primary systemic therapy (PST) - A transSENTINA subproject (2020) (0)
- Abstract GS4-03: Patient-reported outcomes (PROs) for the intergroup sentinel mamma study (INSEMA, GBG75, ABCSG43): Persistent impact of axillary surgery on arm and breast symptoms in early breast cancer (2022) (0)
- Breast cancer during pregnancy: from preclinical models to clinical studies (2022) (0)
- The effect of denosumab on disseminated tumor cells (DTCs) of breast cancer patients with neoadjuvant treatment: a GeparX translational substudy (2023) (0)
- Systematic analysis of parameters predicting pathological axillary status (ypN0 vs. ypN+) in patients converting from cN+ to ycN0 through primary systemic therapy (PST). (2017) (0)
- Abstract P5-07-02: Systematic analysis and modulation of Ki67 interobserver variance in 9069 patients from three clinical trials – How much pathologist concordance is needed for meaningful biomarker results? (2016) (0)
- Impact of Multifocal or Multicentric Disease on Surgical, Locoregional, and Distant Survival After Neoadjuvant Chemotherapy in 3562 Breast Cancer Patients (2012) (0)
- Anti-hormonal maintenance treatment with/without the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in HR+/HER2- metastatic breast cancer: a phase II trial (AMICA) GBG 97 (2018) (0)
- Characterization of Hormone Receptor and HER2 Status in Breast Cancer Using Mass Spectrometry Imaging (2023) (0)
- Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer (2023) (0)
- 137O Tucatinib vs placebo added to trastuzumab and capecitabine in previously treated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB) (2020) (0)
- Meetings and Conferences · Tagungen und Kongresse (2012) (0)
- Reply to D. Crivellari et al. (2014) (0)
- Abstract P3-10-01: Single-cell profiling identifies hypoxic carcinoma cells as source of an immunosuppressive VEGFA metagene (2019) (0)
- TITLE: INTEGRATED ANALYSIS OF PTEN AND p4EBP1 PROTEIN EXPRESSION AS PREDICTORs FOR pCR IN HER2 POSITIVE BREAST CANCER (2015) (0)
- Neoadjuvant Chemotherapy in Women 35 and Under (2013) (0)
- Reporting the Analytical Method Is Essential to Assessing Studies in Which Biomarkers Are a Major Study Objective-Reply. (2021) (0)
- GEFINITIB IN COMBINATION WITH TAMOXIFEN IN PATIENTS WITH OVARIAN CANCER REFRACTORY TO PLATINUM-TAXANE BASED THERAPY – A PHASE II STUDY OF THE AGO OVAR (2004) (0)
- Neoadjuvant breast cancer therapy: the German experience (2008) (0)
- Abstract OT1-14-02: Phase 3 study of trastuzumab deruxtecan (T-DXd) with or without pertuzumab vs a taxane, trastuzumab and pertuzumab in first-line (1L), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (mBC): DESTINY-Breast09 (2022) (0)
- EFFECTS OF BREAST CANCER TREATMENT ON PLACENTAL TISSUE (2018) (0)
- Practice-Changing Perspectives regarding Systemic Therapy in Early Breast Cancer: Opinions of German Experts regarding the 17th St. Gallen International Consensus Conference (2022) (0)
- Magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer (2019) (0)
- Pharma News / Pharma Ticker (2008) (0)
- Contents of Forthcoming Issues · Themenvorschau (2008) (0)
- Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial (2022) (0)
- Abstract PD2-04: Molecular plasticity of luminal breast cancer and response to CDK 4/6 inhibition - The biomarker program of the PENELOPE-B trial investigating post-neoadjuvant palbociclib (2022) (0)
- Inflammatory and locally advanced breast cancer respond similar to operable breast cancer to neoadjuvant chemotherapy: Results from 278 patients with cT4a-d tumors of the GeparTRIO trial (2016) (0)
- Abstract P3-01-09: Maintenance Therapy with ET and Ribociclib after 1st line Chemotherapy (CT) in Hormone Receptor (HR)-positive/HER2-negative Metastatic Breast Cancer (BC): a Phase II Trial (AMICA) (2023) (0)
- Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial (2023) (0)
- Response-based molecular subtyping-emergence of the third generation of breast cancer subtypes. (2022) (0)
- DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status (2021) (0)
- 1422OCTCA toxicity scoring and EORTC quality of life questionnaire: A comparison of physicians’ and patients’ scoring of toxicity in the “Panther trial” (2017) (0)
- 137TiP A phase III study of alpelisib and fulvestrant for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) progressing on or after aromatase inhibitor (AI) therapy (SOLAR-1) (2016) (0)
- Abstract PD17-06: Immunohistochemical markers and determinants of clinical response in the Penelope-B trial (2023) (0)
- GYN 4: phase I study of BIBF 1120 in combination with paclitaxel/carboplatin in patients with advanced gynecological malignancies (2008) (0)
- Tumor infiltrating lymphocytes to predict DFS from intense dose-dense (idd) EPC regimen: Results from the German Adjuvant Intergroup Node-positive study (GAIN-1). (2018) (0)
- Abstract ED4-4: Lobular/pleomorphic Breast Cancer (2023) (0)
- Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis (2022) (0)
- Abstract P4-10-16: Reactive stroma and trastuzumab resistance in HER2-positive early breast cancer (2020) (0)
- Adjuvant Docetaxel in Node-Negative Breast Cancer Patients: A Randomized Trial of AGO-Breast Study Group, German Breast Group, and EORTC-Pathobiology Group (2023) (0)
- Genome-wide association study of germline variants and breast cancer-specific mortality (2019) (0)
- IN22 Breast cancer during pregnancy – the oncologist's point of view (2012) (0)
- 95MO Characteristics of patients with brain metastases from HER2-positive breast cancer (2021) (0)
- Correction: Residual Axillary Burden After Neoadjuvant Chemotherapy (NACT) in Early Breast Cancer in Patients with a priori Clinically Occult Nodal Metastases – a transSENTINA Analysis (2020) (0)
- Association between tumor biology and occult lymph node metastases before and after primary neoadjuvant therapy (NAT) for patients with early breast cancer (2019) (0)
- Correction to "Integration of Metabolomics and Expression of Glycerol-3-phosphate Acyltransferase (GPAM) in Breast Cancer─Link to Patient Survival, Hormone Receptor Status, and Metabolic Profiling". (2022) (0)
- Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer (2022) (0)
- Abstract HER2-06: HER2-06 Outcome analysis of HER2-zero or HER2-low hormone receptor-positive (HR+) breast cancer patients - characterization of the molecular phenotype in combination with molecular subtyping (2023) (0)
- Physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in BRCA-mutated breast cancer (BC) patients (pts): Results from the BCY3/BCC 2017 survey. (2018) (0)
- Evaluation of tumor-associated lymphocytes as a predictor of response to neoadjuvant chemotherapy in breast cancer: Results from the GeparDuo and GeparTrio trial. (2009) (0)
- Abstract #746: Androgen-receptor expression in triple negative breast cancer: Results from the neoadjuvant GeparTrio trial (2009) (0)
- Trastuzumab-Deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual invasive early breast cancer (BC) after neoadjuvant therapy (NAT): a randomized, phase 3 trial (DESTINY-Breast05) (2021) (0)
- Breast Cancer News from Oral Sessions (2020) (0)
- Correction to: TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer (2021) (0)
- TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer (2021) (0)
- 000197 THE ANTI-IDIOTYPIC MONOCLONAL ANTIBODY ACA125 IN PATIENTS WITH RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PERITONEAL CANCER. A PHASE II TRIAL OF THE AGO-OVAR (2005) (0)
- 149P Predicting prognosis of breast cancer patients with brain metastases in the BMBC registry: Comparison of three different prognostic scores (2020) (0)
- Abstract P3-14-04: The choice of the indicator lesion impacts on the pCR rate – An analysis of 114 bilateral breast cancer patients treated within neoadjuvant trials (2013) (0)
- Breast cancers with stem cell-like features delineate endocrine responsiveness (2007) (0)
- Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial. (2023) (0)
- SOFIA: Phase II study of neoadjuvant epirubicin, cyclophosphamide (EC) plus sorafenib (S) followed by paclitaxel (Pw) plus sorafenib (S) in women with primary breast cancer (BC; GBG 45). (2011) (0)
- Evolution of synchronous female bilateral breast cancers and response to treatment (2023) (0)
- Can We Keep the ‘PROMISE’? (2011) (0)
- 10-year results of the International Breast Cancer Intervention Study II (IBIS-II) (2020) (0)
- Contents Vol. 11, 2016 (2016) (0)
- Post-Neoadjuvant Therapy (2019) (0)
- Abstract P6-07-05: Prognosis of 368 women with primary breast cancer during pregnancy: results from an international collaborative trial (2012) (0)
- Mitomycin C in combination with capecitabine (Mi-Cap) as chemotherapy in breast cancer patients with extensive liver metastases and impaired hepatic function: A non-randomized multicentre phase II study (2007) (0)
- Contents Vol. 7, 2012 (2012) (0)
- Serum carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: a biomarker analysis from the GeparQuinto phase III neoadjuvant breast cancer trial (2016) (0)
- [New aspects of carcinoma of the breast therapy and of gynaecological carcinoma treatment]. (2003) (0)
- P1-12-01: Pregnancy during and Following Adjuvant Trastuzumab in Patients with HER2−Positive Breast Cancer: An Analysis from the HERA Trial (BIG 01-01). (2011) (0)
- Abstract P1-10-01: Caveolin gene expression predicts for response and clinical outcomes of patients treated with preoperative paclitaxel-based chemotherapy regimens in early stage breast cancer (2020) (0)
- Acknowledgement of Reviewers (2008) (0)
- 24PPhosphoproteomic assessment of HER2 signaling pathway in HER2 non-amplified patients of the GeparQuattro and GeparQuinto trials (2015) (0)
- Abstract P1-13-04: Higher rate of severe toxicities in obese patients receiving dose-dense chemotherapy according to unadjusted body mass index – Results of the prospectively randomized GAIN study (2016) (0)
- Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 Therapy. (2023) (0)
- Abstract PD3-1: Evaluation and clinical impact of intra-tumor heterogeneity (ITH) in primary HER2-overexpressing breast cancers (HER2+BC) treated with adjuvant trastuzumab and chemotherapy (CT) (2015) (0)
- 1957 Ovarian suppression with luteinizing hormone-releasing hormone agonists during chemotherapy as a strategy to preserve ovarian function and fertility in breast cancer patients: A systematic review and meta-analysis of randomized studies (2015) (0)
- Erratum: Breast Cancer in Young Women - News from the BCY3 Consensus Conference (2017) (0)
- PIK3CA mutations in primary HER2-positive and triple negative breast cancer. (2013) (0)
- Metabolomics of human breast cancer: new approaches for tumor typing and biomarker discovery (2012) (0)
- Impact of nab-paclitaxel dose reduction on survival of the randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy of weekly nab-paclitaxel (nP) with solvent-based paclitaxel (P) followed by anthracycline/cyclophosphamide for patients with early breast cancer (BC). (2018) (0)
- A model for trial level prediction of long term outcome based on pathological complete response (pCR) after neoadjuvant chemotherapy for early-stage breast cancer (EBC). (2016) (0)
- IN8 Neoadjuvant therapy for young women with breast cancer (2014) (0)
- Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: Pharmacokinetic, safety and patients' preference - Substudy of the randomised phase III GAIN-2 study (2022) (0)
- Death during study treatment: An evaluation of events in 31 German clinical trials. (2015) (0)
- 40 Patient Self-reported Outcome for Long-term Follow up of Early Breast Cancer Trials (2012) (0)
- Editorial Board / Contents / Imprint / Contents of Forthcoming Issues (2016) (0)
- Abstract P5-02-32: Differential Gene Mutation Landscape in Patients With PIK3CA-altered and Non-altered Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer in the SOLAR-1 Clinical Study (2023) (0)
- Correction: AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update (2021) (0)
- PEGLIPOSOMAL DOXORUBICIN (PLD) AND CARBOPLATIN (C) FOR GYNAECOLOGICAL TUMOURS – PHASE I/II-STUDY FROM THE AGO OVARIAN CANCER STUDY GROUP (2004) (0)
- Application of CDK4/6 inhibitors in practice: Effect of online education on clinician competence and confidence. (2018) (0)
- Expression and prognostic role of angiogenic and cell-cycle markers in serous ovarian carcinomas. (2007) (0)
- Title Page / Table of Contents / Imprint / Guidelines for Authors (2015) (0)
- [Diagnosis and therapy of breast cancer--meeting highlights ASCO 2005]. (2005) (0)
- Abstract P3-11-01: Neoadjuvant chemotherapy with or without bevacizumab or everolimus: Survival analysis of The HER2-negative cohort of the GEPARQUINTO study (GBG 44) (2015) (0)
- 18 Breast Cancer in the Young (2012) (0)
- Breast Cancer During Pregnancy (2020) (0)
- Abstract GS5-02: Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency – long-term survival of the GeparOLA study (2023) (0)
- Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy (2023) (0)
- Abstract P5-16-03: Peripheral sensory neuropathy occurrence and resolution: Results from the neoadjuvant randomized GeparSepto study (GBG 69) (2017) (0)
- 58PConcordance of local and central HER2 status in 1597 patients participating in German neoadjuvant breast cancer studies (2015) (0)
- Effect of estrogen receptor beta expression (ERße) in triple-negative breast cancer (TNBC) patients treated in the neoadjuvant GeparTrio trial. (2011) (0)
- Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness (2021) (0)
- Alpelisib (ALP) + fulvestrant (FUL) in hormone-receptor positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Subgroup analysis by presence of visceral metastasis (VM) in the SOLAR-1 trial (2019) (0)
- Congress Reports · Kongressberichte (2011) (0)
- VEGF-A and COX-2 expression correlate with platinum resistance in ovarian cancers. (2006) (0)
- Abstract OT1-02-01: Phase III postneoadjuvant study evaluating sacituzumab govitecan (SG), an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment - SASCIA (2022) (0)
- Abstract 896: Serum-vascular endothelial growth factors (sVEGF) A and C have a potential as predictive tests for neoadjuvant bevacizumab in primary breast cancer (2014) (0)
- Quality of patient-reported outcome for long-term survival of early breast cancer trials. (2016) (0)
- Abstract P2-12-03: Phenotype shifting in early breast cancer with and without primary systemic treatment: A retrospective cohort analysis correlating core needle biopsies and excisional biopsies in 1250 consecutive real-world cases (2022) (0)
- A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer (2018) (0)
- Sixteen months follow-up of health related quality of life in women with high-risk breast cancer after random assignment to adjuvant treatment with tailored dose-dense chemotherapy vs standard three-weekly adjuvant chemotherapy (PANTHER study) (2017) (0)
- A randomized, open-label, phase IV study evaluating palbociclib plus endocrine treatment versus a chemotherapy-based treatment in patients with hormone receptor-positive, HER2-negative metastatic breast cancer (PADMA) (2018) (0)
- „Es gibt keine absolute Kontraindikation zur brusterhaltenden Operation“ (2013) (0)
- Author reply (0)
- Meeting and Conferences (2008) (0)
- HR-MAS proton NMR based metabolomic analysis of breast cancer tissues highlight the importance of choline metabolites in tumour grading (2010) (0)
- EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy (2022) (0)
- Fatal events during clinical trials: an evaluation of deaths during breast cancer studies (2019) (0)
- Inferred immune-cell activity is an independent predictor of HER2 negative breast cancer prognosis and response to paclitaxel-based therapy in the GeparSepto trial. (2023) (0)
- Anti-hormonal maintenance treatment with or without the CDK4/6 inhibitor ribociclib after first line chemotherapy in hormone receptor positive/HER2 negative metastatic breast cancer: A phase II trial (AMICA) GBG 97. (2018) (0)
- Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy (2022) (0)
- A PLAIN-LANGUAGE SUMMARY OF THE SOLAR-1 TRIAL: STUDYING ALPELISIB WITH FULVESTRANT IN PATIENTS WITH HR+, HER2– ADVANCED BREAST CANCER WHO HAD PREVIOUSLY RECEIVED AN AROMATASE INHIBITOR (2019) (0)
- Prognostic score for Luminal A-like breast cancer patients. (2014) (0)
- Abstract OT3-26-02: A Phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a non-steroidal aromatase inhibitor (VIKTORIA-1) (2023) (0)
- Correction: MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial (2021) (0)
- Abstract OT1-07-01: Omission of SLNB in triple-negative and HER2-positive breast cancer patients with radiologic and pathologic complete response in the breast after NAST: a single-arm, prospective surgical trial (EUBREAST-01 trial, GBG 104) (2023) (0)
- Breast Cancer in Young Women - News from the BCY3 Consensus Conference (2016) (0)
- Abstract PD2-02: Longitudinal ctDNA sequencing using an expanded genomic panel in the PALOMA3 trial of palbociclib plus fulvestrant (2019) (0)
- Diagnose der pathologischen Komplettremission nach neoadjuvanter Chemotherapie bei Brustkrebs mittels minimal invasiver Biopsietechniken (2015) (0)
- Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2–) advanced breast cancer (ABC): subgroup analysis of 2 randomized phase 3 studies (2018) (0)
- Abstract P3-07-55: Predictive value of O6-methylguanine-DNA methyltransferase (MGMT) promoter gene methylation in triple-negative breast cancer patients receiving carboplatin (2016) (0)
- PATH – Patients Tumorbank of Hope (2008) (0)
- [New strategies for therapy of breast cancer. San Antonio Breast Cancer Symposium, 2002]. (2002) (0)
- Personalized medicine—from translational research to clinical practice (2023) (0)
- News from the San Antonio Breast Cancer Symposium 2010 (2011) (0)
- Abstract P6-10-04: Landscape of immune-cell signatures in early high-risk breast cancer (BC) reveals clinically-relevant enrichment of immune subpopulations (2020) (0)
- 0074: Combination Therapy with Pegliposomal Doxoru-Bicin and Carboplatin in Gynecologic Tumours. a Phase-Ii Trial of the Ago-Ovar and the Ago Kommission Uterus (2006) (0)
- Abstract DEB1-2: Con - RxPONDER: Was it all OFS? (2022) (0)
- HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer (2013) (0)
- Breast cancer in Pregnancy (BCP) Prospective and Retrospective Registry Study of the German Breast Group (GBG) for Diagnosis and Treatment of Breast Cancer in Pregnancy compared to young non-pregnant women (2014) (0)
- First-in-Class-Therapie mit Sacituzumab Govitecan (2022) (0)
- Abstract PD8-03: Conversion rates from positive to negative axillary involvement in breast cancer patients presenting with biopsy-proven axillary metastases prior to primary systemic therapy (PST) – A transSENTINA subproject (2019) (0)
- Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancer. (2022) (0)
- Association of clinical/pathological parameters with axillary involvement in early breast cancer in patients with limited sentinel node involvement after neoadjuvant chemotherapy (NACT) (2018) (0)
- Breast Cancer in Young and Premenopausal Women (2019) (0)
- Outcome after neoadjuvant chemotherapy in progesterone receptor negative breast cancer patients - A pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials (2017) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Sibylle Loibl*?
Sibylle Loibl* is affiliated with the following schools:
- University of Cambridge
- Goethe University Frankfurt
- University of Western Ontario
- Medical University of Vienna
- Institute of Cancer Research
- KU Leuven
- University of Regensburg
- University of California, Los Angeles
- Kiel University
- University of Basel
- National Taiwan University
- Technical University of Munich
- Seoul National University
- Tampere University
- University of Rostock
- Complutense University of Madrid
- University of Nottingham
- Hannover Medical School
- University of Edinburgh